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ABSTRACT 
PROTEIN BEHAVIOUR DIRECTED BY HEPARIN CHARGE AND CHAIN 
LENGTH 
 
MAY 2014 
 
BURCU BAYKAL MINSKY 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Paul L. Dubin 
 
Glycosaminoglycans (GAGs), highly charged biological polyelectrolytes, are of 
growing importance as biomaterials and pharmaceutical drugs due to their immense 
range of physiological functions. They bind to many proteins; however, the degree of 
structural selectivity in GAG-protein interactions is largely unknown .Our studies have 
focused on the importance of heparin (a model GAG) charge and chain length in protein 
binding in order to explore its potential applications in biofunctional tissue scaffold 
materials, as polysaccharide drugs in anticoagulation, and as inhibitory agents in protein 
aggregation. We used electrospray ionization mass spectrometry, capillary 
electrophoresis, size exclusion chromatography, dynamic/static light scattering and 
electrostatic protein modeling. 
viii 
 
Our studies, in the order of presentation in this thesis, showed first that the 
electrophoretic mobility of Hp oligomers varies inversely with chain length, which is 
explained by reduced counterion condensation at the chain ends or junctions. This 
provides an important insight into the biological relevance of sulfation patterns. Second, 
charge driven interactions among acidic fibroblast growth factor (FGF), tetralysine (K4) 
and heparin decamer (dp10) indicated qualitatively that K4-dp10 complex formation is 
consistent with binding being driven by the release of condensed counterions, whereas 
FGF-dp10 binding is driven primarily by screened electrostatics. Third, FGF binding to 
heparin octamer and decamer chains showed that protein:heparin mixing ratio modulates 
multiple protein binding equlibria, and highly sulfated chains facilitate the formation of 
multimeric FGF complexes. Next, the effects of heparin chain length on the complexation 
between antithrombin (AT) and Factor Xa (FXa) were studied: Shorter heparin oligomer 
chains induced binary AT·FXa complexes, while longer chains facilitated AT·FXa·dp20 
ternary complexes. We used native heparin chains, which represent an extreme case of 
heterogeneity to investigate binding properties with AT. Using a recently developed mass 
spectrometry method, limited charge reduction, 1:1, 2:1 and 1:2 (AT:Hp) complexes were 
detected. Finally, differences between inhibition and reversal of aggregation by heparin 
were observed for AT and BSA aggregations; inhibition may depend on the stage at 
which Hp enters the aggregation process, and reversal depends  on aggregate size and 
morphology.  
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CHAPTER 1 
BACKGROUND ON HEPARIN AND HEPARIN -PROTEIN INTERACTIONS 
1.1 Glycosaminoglycans (GAGs) 
GAGs are negatively charged linear polysaccharides found on cell surfaces, in the 
extracellular matrix (ECM) and in connective tissue mast cell granules (Figure 1.1). They 
bind to a multitude of proteins including growth factor/morphogen families and receptors, 
enzymes, enzyme inhibitors, cytokines, chemokines, cell adhesion molecules and various 
extracellular matrix components to potentiate cell proliferation, differentiation, adhesion, 
wound healing, inflammation, embryonic development, homoeostasis, anticoagulation 
and amyloidogenesis.
1
 The GAG family is classified into four groups depending on the 
saccharide structure, glycosidic bond type and the location of sulfates. These groups are: 
(1) heparin (Hp)/heparan sulfate (HS), (2) dermatan sulfate (DS)/ chondroitin sulfate 
(CS), (3) keratan sulfate (KS) and (4) hyaluronic acid (HA). Their structure consists of 
repeating disaccharide units of a hexuronic acid and a hexosamine, either or both can be 
decorated with sulfate groups at various positions (excluding hyaluronic acid). GAGs are 
covalently linked to highly glycosylated core proteins through serine residues to form 
proteoglycans (PGs).
2
 PGs are highly diverse with respect to type of the core protein, size 
and composition of GAG chains. In the GAG family, HS is expressed in almost all cells,
3
 
exhibits structural diversity in a tissue-specific manner,
4
 and  is particularly important in 
the modulation of critical cellular functions.  Heparan sulfates exert their functions by 
protein binding; however, the way in which polydispersity modulates protein binding is 
not well understood.  
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Representation of GAGs in the ECM, on the cell surface and in the mast 
cell granules (Adapted from ref. 3). 
 
1.1.1 Heparan Sulfate and Heparin 
The versatility of HS, playing the roles noted above for many growth factors, 
arises from its structural variability, seemingly random but in fact exquisitely regulated.
5,6
 
After the synthesis of the polysaccharide backbone, the polymer chain undergoes a series 
of modifications involving epimerization (transformation of glucosamine unit to L-
iduronic acid) and the addition of sulfates to various positions by N- and O-
sulfotransferases (Figure 1.2).  
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Figure 1.2: Repeating disaccharide unit structure of heparin and heparan sulfate 
 
HS is consequently composed of repeating disaccharide units of N-acetylated 
(GlcNAc)/N-sulfated glucosamine (GlcNS) and glucuronic acid (GlcA) or iduronic acid 
(IdoA).
7
 The enzymatic modifications do not occur uniformly across the entire chain 
during the synthesis; instead, the resultant structure exhibits “domains” of high sulfation, 
rich in IdoA and O-sulfation (NS); non-sulfated but N-acetylated (NA) regions; and 
alternating NS/NA domains.
8
 Heparin (Hp) structurally related to HS, but in the mast cell 
granules, plays a different role by modulating proteins of the coagulation cascade.  Hp 
resembles extended NS domains of HS (Figure 1.3) and contains higher degrees of N- 
and O-sulfation.
2
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Figure 1.3: Schematic representation of the sulfate distribution on the Hp and HS.  
 
Because these domains are more involved in protein binding events, Hp is 
commonly used in studies of GAG-protein interactions as a proxy for HS, and their 
similarity prompted the use of the term “heparinoid.” In most studies related to GAG-
protein interactions, GAG structure is depicted as rigid, and the dynamic nature of these 
highly charged polysaccharides in solution have not been given enough attention.
9,10
   
1.2 Polyelectrolyte properties of GAGs 
An essential feature of nearly all polyelectrolytes in solution is flexibility, 
stochastic chain dimensions, and characteristic dependences of chain dimensions on MW 
and ionic strength. GAGs have exceptionally high linear charge density arising from 
extensive post-translational sulfation. Heparin was first recognized as  an anionic 
polyelectrolyte almost 35 years ago.
11
 A variety of physicochemical studies have 
demonstrated the polyelectrolyte properties of GAGs. For example, Pavlov et al. 
characterized heparin as a semi-flexible, worm-like chain.
10
 Bertini et al. employed high 
performance-size exclusion chromatography (HP-SEC) with triple array detector to 
calculate molecular weight and molecular weight distributions of full-length heparin, 
heparin fractions and dermatan sulfate. Consistent with the worm-like chain model, they 
found intrinsic viscosity [ ] to scale with MW
0.84. Different GAG’s exhibited different 
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MW-dependence of [ ] and the radius of gyration.
12
 Guo et al. showed that accurate 
measurement of MW’s of heparin by size exclusion chromatography required salt (1M) 
to screen electrostatic interactions of heparin with the column packing.
13
 These 
experimentally supported properties of GAGs coincide with the general polyelectrolyte 
behavior, such as displaying various levels of flexibility in solution depending on their 
repeat units, having no secondary structure and readily interacting with oppositely 
charged surfaces.  
1.3 GAG-Protein Interactions 
 
While GAGs have tremendous potential in therapeutic applications and 
regenerative medicine, their structure-function relationships are not well understood due 
to intra- and inter-chain heterogeneity. This heterogeneity allows them to interact with 
numerous proteins to potentiate critical cellular functions (Figure 1.4); however, the 
nature and degree of specificity and selectivity in protein binding (a unique set of GAG 
sequence arrangements for each protein cognate) is still a matter of debate. The concept 
of specificity has been associated with precise GAG sequences that interact with proteins 
via pair-wise interactions. In this perspective, the contributions of sulfate groups at 
specific locations has been thought to play prominent roles; this model initiated 
fingerprinting studies to determine key heparin/HS sequences that are involved in protein 
binding.
14-18
 The attempts to unlock signature structural features of GAGs have been 
partially achieved only for antithrombin,
18,19
 but failed in many cases, especially for 
growth factor/morphogen binding.
20-22
 The high charge density, stochastic sulfate groups 
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distributions , and configuratioal flexibility of GAGs, which could be retained partially at 
the bound state could lead a definition of "electrostatic epitopes" , as opposed to well 
defined and unique binding motifs. This lack of consensus on the structural requirements 
in protein recognition points toward the need for alternative explanations to define the 
nature of GAG-protein binding.  
 
 
Figure 1.4: Suggested roles of Hp and HS 
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1.3.1 Conventional models in protein-Hp binding  
In protein-ligand interactions, high-affinity invokes the “lock” and key” analogy 
for protein (host) and (small) ligand (guest). However, applying a similar analogy to 
protein-GAG systems neglects the inversion of the host-guest relationship. On the other 
hand, native GAG chains are replaced by low MW analogs in many studies, with the 
characterization of protein-oligoheparin complexes based on crystallography,
23-25
 docking 
or MD simulations.
26
 The Antithrombin-pentasaccharide model  (Figure 1.5) epitomizes 
this perspective, positing a distinctive sequence on the Hp chain that interacts specifically 
with AT:
27
 i.e. a specific pentasaccharide is required to activate AT towards coagulation 
protease, FXa in the anticoagulation. However, this model failed to take into account the 
configurational flexibility of Hp, and the enormous diversity of chemical structures, in 
particular sulfation sequences.  
 
Figure 1.5: a) Crystal structure of AT and pentasaccharide; b) suggested hydrogen 
bonding (dashed lines) and salt bridges (solid lines) between AT residues and 
pentasaccharide charged groups.
23
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1.3.2 Alternative models in protein-Hp binding 
The pentasaccharide model is increasingly viewed as a “gross approximation”, of 
limited applicability for GAG-protein interactions in general.
9,28,29
 Studies of tightly 
bound MW heparin analogs can be misleading, because enthalpic contributions are 
overemphasized, while entropic contributions are underestimated.
30
 Furthermore, recent 
Monte Carlo simulations formerly done for a heparin-mimetic binding to BSA,
31
 which 
we now extend to AT (Figure 1.6), point clearly to a dynamic form of binding in which 
conformational flexibility of the polyelectrolyte is not lost in the bound state (consistent 
with current ideas of “plasticity” and “promiscuity”). 9,32 
The dynamic nature of GAGs was also considered by Lander et al. who 
emphasized the contribution of GAG in binding kinetics rather than thermodynamics.
33
  
He proposed that GAGs act catalytically on the cell surface to capture growth factors and 
growth factors receptors. In blood coagulation, heparin basically increases the rate of 
Antithrombin-Thrombin or Antithrombin-Factor Xa interaction. Accordingly, the 
interaction can be considered in two steps: encounter and reaction. The first is driven by 
the physics of diffusion for the binding on the same heparin chain of AT and the 
coagulation protease, with the GAG chain acting as a surface to capture the interacting 
partners.  Similarly, on cell surfaces, HS proteoglycans increase the rate of growth factor 
and receptor encounters by decreasing the dimensionality from 3-D to 2-D.
33
  
Early views of specificity, i.e., the nature of the role of Hp/HS sequence in GF 
recognition, have been challenged by recent findings of promiscuity of binding between 
highly sulfated GAG chains and growth factors. Empirically, the correlation of GAG 
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sulfate density with GF binding appears to exist somewhat independently of precise 
location of sulfate groups. For example, Catlow et al. showed that the interaction of 
hepatocyte growth factor/scatter factor (HGF/SF) with HS is dominated by electrostatics 
and that HS sulfate density affects the selectivity.
34
 Krueger et al. found that various 
FGFs share the same binding domain on HS, with affinity correlated with the level of 
sulfation.
21
 Jastrebova et al. found correlation between overall O-sulfation levels and the 
stability of the FGF-receptor-HS.
35
 Zhang et al.  showed that the higher degree of 
sulfation on heparin chains is preferred in interleukin 7 (IL-7) interactions.
36
 These 
findings point to the need for a new concept of GAG-protein specificity that considers 
charge complementarity between the protein and the related polyanion, i.e. “there is an 
intermediate specificity based on the gradient of electrostatic interactions that are a 
function of relative charge densities, in contrast to high conformationally based structure 
specificity.”37 In addition, arrangements of NS and NA blocks have been shown to 
provide functional domains for protein binding.
38
 For example the interferon-gamma 
(IFN ) binding site consists of 24 disaccharide units contains two terminal sulfated 
domains, each binding to one IFN  monomer,
39
 and separated by a nonsulfated G1cA-
rich sequence. Similar binding site exists for platelet factor 4 (PF4),
40
 interleukin-8 (Il-
8),
41
 RANTES
42
 and vascular endothelial growth factor (VEGF).
43
 Most of these proteins 
are either multimeric in solution or multimerized upon binding to HS. 
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Figure 1.6: Coarse-grained Monte Carlo simulation showing the mobility of bound 
synthetic polyanion resides on the positive domain of AT, but never stops moving (I 
=10mM, pH=6.8). Red and blue correspond to the negative and positive potentials, 
respectively and they have been calculated using non-linear Poisson- Boltzmann 
equation (Courtesy of Daniel Seeman).  
 
1.4 Roles of electrostatics in Hp-Protein binding 
Heparin-protein binding affinity arises principally from the electrostatic 
interactions common to polyelectrolyte-protein systems,
44,45
 for which different models 
have been widely applied. One model inspired by theories for the salt dependence of 
oligolysine-DNA interactions,
46,47
 has been applied to DNA-protein binding. The linear 
dependence of log Kobs (equilibrium association constant) on log I (ionic strength) is 
consistent with a purely entropic Gobs, which arises from the release of DNA 
counterions (Figure 1.7). However, directly replacing oligolysines with proteins fails to 
consider the influence of protein charge anisotropy.
48
 Nevertheless, extension of this 
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treatment to Hp-protein binding yields a physically realistic value of Hp structural charge 
density deduced from measured dlogKobs / dlog I.
49
  
 
 
 
 
 
 
 
 
 
 
Figure 1.7: The dependence of association equilibrium binding constants Kobs on 
the salt concentration for KWK-CO2 (●) and RWR-CO2 (○) interactions with 
heparin (from ref. 49) 
 
On the other hand, many polyelectrolyte-protein systems show clearly different 
salt dependence more consistent with Debye-Hückel screening.
44,50
 This last model takes 
into account protein charge anisotropy, and effectively accounts for the non-monotonic 
salt dependence seen when polyelectrolytes (e.g., heparin) bind to proteins with net 
charge of the same (i.e. negative) sign, through a domain of opposite (i.e. positive) 
charge, best identified through representation via protein charge calculations.
51
 Therefore, 
it is possible to account for the observed salt dependence of protein-Hp binding by using 
specific models of heparin binding along with quantitative protein visualization.
28,51
 Non-
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monotonic ionic strength dependence was observed for AT binding of both full length 
and low molecular weight heparin. In this system, maximum binding occurs at 5 < I < 30 
mM (Figure 1.8), where the Debye length (κ-1~0.3/√I) is closer to the protein radius 
(indication of the combination of short range attractions and long range repulsions).
28
   
 
 
 
 
 
 
 
Figure 1.8: Non-monotonic salt dependence of AT binding with Hp and low 
molecular weight heparin, tinzaparin using frontal analysis continuous capillary 
electrophoresis (FACCE), from ref. 28.  
1.5 Low Molecular Weight Heparins: Therapeutic Significances  
The structural complexity of heparin is the major barrier for therapeutic 
applications of heparin. In order to reduce this complexity, efforts have emerged to 
generate low molecular weight Hp chains, which are composed of enzymatically or 
chemically depolymerized native heparin chains (MW 5,000 to 8,000 Da). The 
commercially available low molecular weight heparin analogs exhibited longer plasma 
life time than native heparin and have been safely applied in the treatment of 
anticoagulation and venous thromboembolism.
52
  In addition, reduced heterogeneity 
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facilitates characterization of these Hp analogs and investigation of their protein 
interactions using various analytical tools. Accordingly, the small molecule Hp surrogates 
improve the “applicability” of certain experimental technique; however, such 
oversimplified surrogates of native Hp could deviate from the biologically relevant 
counterparts (Figure 1.9). Thus, there should be an adequate balance between 
“engineered” selective Hp chains and the biologically relevant Hp chains that could 
initiate substantial cellular response.  
 
 
 
 
 
 
 
 
 
Figure 1.9: Schematic representation of the chain length and biofunctionality 
relationship of Hp  
 
1.6 Aim and Outline of the Thesis 
The purpose of this thesis is to elucidate structure-activity relations in 
glycosaminoglycan-protein binding. These are not well understood due to the immense 
polydispersity of heparin (Hp), the model GAG.  The effects of GAG overall sulfation, 
saccharide sequence arrangements and chain length are still controversial.  To address 
these issues, electrospray ionization mass spectrometry, capillary electrophoresis and 
dynamic light scattering were applied to systems of Hp and its oligomers in combination 
with either Antithrombin (AT) or Fibroblast Growth Factor (FGF). The effects of heparin 
 
14 
 
chain length and charge density were investigated in directing protein behavior, i.e., 
inducing complex formation or modulating higher-order protein assemblies.  
The physicochemical properties of native heparin and heparin oligomers were 
studied using capillary electrophoresis and electrospray mass spectrometry (ESI-MS) as 
presented in chapter 2.  This study indicates an inverse relationship between chain length 
and electrophoretic mobility of heparin oligomers, which can be explained by a recent 
theory of polyelectrolyte end effects. Chapter 3 explores mechanistic differences in the 
binding of a heparin decamer binding to a growth factor vs. an oligopeptide, with 
consideration of potential applications of heparin oligomers in tissue scaffolds. The effect 
of heparin oligomer chain length and charge density in FGF-1 binding and the induction 
of multimeric complexes of FGF-1 are demonstrated in chapter 4. Chapter 5 explores the 
heparin chain length dependence of FXa binding, focusing on the capabilities of various 
length Hp oligomers to induce binary and ternary complexes (chapter 5). In addition to 
Hp oligomers, AT and native heparin complex formation were studied using a recently 
evolved technique, limited charge reduction with FTICR MS, and these results are 
presented in chapter 6. Finally, studies that show inhibition and reversal of aggregation of 
antithrombin and bovine serum albumin by native heparin are presented in Chapter 7.  
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CHAPTER 2 
COUNTERION CONDENSATION ON HEPARIN OLIGOMERS 
Minsky, B. B.; Atmuri, A.; Kaltashov, I. A.; Dubin, P. L. Counterion Condensation on 
Heparin Oligomers. Biomacromolecules 2013, 14, 1113-1121. 
2.1 Abstract 
The electropherogram of native heparin shows a broad distribution of mobilities µ 
which truncates abruptly at a notably high µ = 4.7x10
-4
 cm
2
V
-1
s
-1
. This highly skewed 
mobility distribution is also found for the 20-saccharide chain which shows from mass 
spectrometry a more uniform (symmetrical) with respect to sulfation level.  Since a 
partially degraded heparin exhibits oligomer peaks with µ> 5x10
-4
 cm
2
V
-1
s
-1
 (appearing 
to escape the limitation of the mobility value for native heparin), we examined the 
electrophoretic behavior of chain-length monodisperse heparin oligomers.  Their 
mobilities varied inversely with the logarithm of the contour length L, for L from 3 to 10 
nm and reached an asymptotic limit for L> 20 nm. The generality of this effect was 
indicated by similar behavior for oligomers of poly(styrenesulfonate). A recent theory of 
polyelectrolyte end effects (Manning, G. S. Macromolecules 2008, 41, 6217-6227.), in 
which chain termini exhibit reduced counterion condensation was found to account 
quantitatively for these results. A qualitative explanation for the anomalously high value 
of µ of native heparin, 10-20% higher than those seen for synthetic polyelectrolytes of 
higher linear charge density is suggested on the basis of similar junction effects 
(Manning, G. S. Macromolecules 2008, 41, 6217-6227.), which reduce counterion 
condensation at the interfaces of regions of high and low sulfation. We suggest that these 
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effects should be considered in models for the biofunctionality of the regulated high and 
low sulfation (NS/NA) domains of heparan sulfate.  
2.2 Introduction 
The ability of glycosaminoglycans (GAGs) to biofunctionally bind a multitude of 
proteins is related in some way to their immense heterogeneity and variable sulfation 
patterns, but this same heterogeneity poses a problem for virtually all methods of 
investigation. GAGs are the most highly charged macromolecules in animals, and their 
affinity for proteins must involve significant electrostatic forces, including even long-
range repulsions from the globally negative charge of most “heparin-binding 
proteins”.9,28  Evidence exists that the negative charge arising from GAG sulfation is 
modified by counterion condensation, a well-established phenomenon for both natural
53-
57
 and synthetic
58,59
 polyelectrolytes. The biophysical consequences of this are not 
understood, even though counterion release is likely to play a role in GAG-protein 
binding.
49
 The issue is further complicated by the immense intrinsic heterogeneity of 
GAGs and the corresponding polydispersity of sulfation patterns, a central problem in 
efforts to resolve GAG structure-function relations.
30,45
 Electrophoretic mobility 
measurements have provided direct validation of counterion condensation,
58-62
 but 
electropherograms of native heparin are naturally quite complex.
63
 Heparin oligomers 
provide a level of simplification suitable for electrophoresis in conjunction with 
electrospray ionization mass spectrometry (ESI-MS). 
The key to structure-function relations for GAGs clearly involves elucidation of 
their sulfation patterns;
22,64
 regulation of sulfation facilitates their roles in angiogenesis, 
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cell signaling, proliferation, and blood coagulation.
2,65-67
 After elongation, heparin/HS 
chains are subjected to enzymatic modifications as opposed to being produced by a direct 
genetic template. The final chains exhibit continuous domains of N-sulfation, N-
acetylation and N-sulfation (NS/NA-domains), and unmodified N-acetylation (NS, 
NA/NS, and NA-domains).
7,68
 Epimerization and O-sulfation then preferentially occur in 
the vicinity of NS domains.  Contrary to HS, heparin does not have “domains” of 
sulfation, but instead extended O-sulfated NS domains.  In this way, heparin serves as a 
good model to examine the way in which high charge density is a central feature in the 
affinity for multiple proteins.   
Elucidation of heparin-protein energetics has proceeded by analogy to DNA-
protein energetics, which rests on measurements of the ionic strength dependence for 
DNA-oligolysine interactions
47,69
 subsequently extended to DNA-protein binding.
70
 Two 
distinct models have generally been invoked to explain the suppression of 
polyelectrolyte-protein binding with added salt.  The first evolved from counterion 
condensation theory developed by Manning,
54,55
 and extended by Record
69,70
 to identify 
the release of sodium ions from DNA as a driving force for its binding to oligolysines. 
Conceptually replacing DNA with heparin, Lohman and Mascotti
49
 measured the salt-
dependent binding constants for heparin with cationic peptides and concluded that a 
purely entropic Gobs arises from the release of heparin counterions. Replacing 
oligolysines with proteins, however, raises the possibility of the influence of protein 
charge anisotropy entirely absent in the DNA-oligolysine model.
48
 A distinctly different 
salt effect arises from screening characterized by the Debye-Hückel screening length 
-1
, 
9,28,51 
which takes into account the decay of small ion imbalance near the macroion, an 
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effect completely distinct from the expulsion of condensed counterions to the bulk 
solution in the Manning
54,55
 and Record
69,70
 models.  
While experiment suggests that heparin may be subject to counterion 
condensation, GAGs introduce a level of heterogeneity not encountered with DNA, 
olioglysines, or proteins. Counterion condensation theory states that the polyelectrolyte 
effective linear charge density is lower than the structural charge density when the 
average spacing between charges b is smaller than the Bjerrum length lb (The latter , lb, is 
the distance between two unit charges at which the Coulomb free energy is thermal 
energy, kBT). When   = lb/b >1, the ionic distribution around the polyelectrolyte is not 
stable; therefore monovalent counterions condense to reduce  to 1. Evidence for 
counterion condensation on GAGs arises from several facts: NMR shows that calcium 
ion binding to heparin does not follow a mass-action law;
71
 chondroitin sulfate and 
keratan sulfate exhibit similar osmotic activities despite the higher sulfation of the 
former;
72
 and the effective charge of heparin from the Donnan distribution is much less 
than its structural charge.
73
 GAG heterogeneity, while recognized, could not be explicitly 
treated in these studies. Inter- and intra-chain heterogeneity of these GAGs seriously 
complicates application of the original counterion condensation theory, a challenge which 
can be greatly simplified with heparin oligomers monodisperse with respect to chain 
length. 
This reduction of polydispersity makes it possible to take advantage of high 
resolution methods: capillary electrophoresis (CE) and mass spectrometry (MS). CE was 
used to measure the mobilities of single stranded DNA oligomers of variable charge 
density at fixed length, or variable degree of polymerization (dp) and at fixed charge.
74
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For heparin oligomers, the resolving power of CE has been mainly directed towards 
characterization of the structural heterogeneity of oligomers.
75-79
 Since MS of GAGs 
provides a description of the distribution of sulfation levels,
80-83
 it can be complementary 
to CE which provides a description of the distribution of mobilities.
84,85
 Of special 
interest here is the relationship between electrophoretic mobility and sulfation level, since 
the dependence of mobility on structural charge density has been a central feature in 
studies validating counterion condensation.
58,63,73,86
 
Here we measure mobility distributions for “clinical” heparin, low-MW heparin, 
and paucidisperse heparin oligomers from hexasaccharide to icosasaccharide (dp6-20), 
and compare them to distributions of mass and sulfation levels, and distributions of 
effective sizes, obtained by ESI-MS and SEC, respectively. The mobilities for the most 
highly sulfated components of the oligomers all show the same inverse length 
dependence as seen in oligomers of PSS in 2-25 nm regime,
58,84
 but contrary to the 
behavior of oligomers of single-stranded DNA.
74
 Our results for the heparin oligomers in 
the 2-25 nm length regime is in good agreement with a theory for counterion 
condensation subject to end effects.
87
 The results are directly relevant to thermodynamic 
analyses put forward for the binding of heparin oligomers to proteins, and have 
implications for the contribution of counterion release to the binding of proteins to 
heparin chains with regulated patterns of sulfation.  
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2.3 Experimental 
2.3.1 Materials 
Heparin hexa, octa, deca and icosasaccharides (dp6, dp8, dp10, dp20) generously 
donated by Dr John Gallagher from Iduron, were prepared by partial heparin lyase 
digestion, followed by high resolution gel filtration. Full-length “native” heparin was 
purchased from Sigma. Low molecular weight heparin, tinzaparin, (5000 Da) provided by 
LEO Pharma (Ballerup, Denmark), was prepared by enzymatic depolymerization. Native 
heparin contains longer heparin chains, with average 50-disaccharide units, and 
tinzaparin includes 2 - 24-mer chains. 
2.3.2 Methods 
2.3.2.1 Capillary Electrophoresis (CE)  
Capillary electrophoresis (CZE) of heparin oligomers was performed using an 
Agilent instrument equipped with a diode array multiple wavelength detector. The runs 
were monitored at 200 and 232 nm.  An uncoated fused silica capillary with dimensions 
50 µm x 33 cm (24.5 cm effective) was used. The voltage applied across the capillary 
was fixed at 12 kV, and the temperature was maintained at 25.0 °C. The injection of the 
samples was done in hydrodynamic mode, applying 50 mbar for 3 seconds at the inlet 
capillary. New columns were rinsed for one hr with 1 N NaOH, followed by one hr with 
Milli-Q-H2O. Between each run, the capillary was reconditioned for 3 min with 0.1 N 
NaOH, followed by water and run buffer. The concentrations of heparin oligomers (dp6-
dp20) were 1 g/L, native Hp was 5 g/L and tinzaparin were 7 g/L. This difference in 
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concentration between Hp and Tz has no effect on the results, inasmuch as identical 
electropherograms are obtained over the range of 1-5 g/L for either heparin or Tz. 
Heparin oligomers were run in triplicate to verify reproducibility.  The run buffer was 
10mM sodium phosphate at pH 6.8. The electrophoretic mobility was calculated as: 
)
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 Eq. 2.1 
where v0 and v1 (cm s
-1
) are the electroosmotic velocity (EOF) and solute velocity, 
respectively; E is the strength of the applied electric field (V cm 
-1
); LD is the effective 
length of the capillary, and LT is the total length of the capillary (cm); V is the applied 
voltage; and tm and ts are the migration times of the reference marker (mesityl oxide) and 
the sample, respectively.  
2.3.2.2 Mass Spectrometry (MS) 
Stock solutions (2 g/L) of dp6, dp8, dp10 and dp20 in water, were diluted to 10 
µM with 10mM NH4Ac. Mass spectra for dp6-10 were obtained using a QStar-XL hybrid 
quadrupole-time-of-flight MS equipped with a nano-ESI-source (AB Sciex, Toronto, 
Canada). Sulfate group loss was minimized by applying mild desolvation parameters 
(Declustering potential (DP): 40, Focusing Potential (FP): 150, DP2: 15). The  
representation of the assigned peaks follows the Roepstorff-Henriksen nomenclature,
80
 
(X,Y,Z), where X = degree of polymerization, Y = number of sulfate groups and Z = 
number of acetyl groups. All MS analysis for dp6-10 were carried out in the positive ion 
mode; therefore NH3 adduct formation was observed depending on the level of sulfation. 
The extent of NH3 adduct formation was determined using the correlation between charge 
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state and the number of adducts provided by Abzalimov et al. for heparin hexamer.
88
 The 
mass measurement of dp20 sample was carried out with a Bruker's SolariX  fourier 
transform  ion cyclotron resonance mass spectrometer (FT-ICR  MS) equipped with a 7-T 
magnet (Bruker Daltonics, Billerica,MA) using internal calibration at a 100 000 mass 
resolution.  
2.3.2.3 Size Exclusion Chromatography (SEC) 
The hydrodynamic size distribution of native heparin and tinzaparin were 
determined on a TOSOH SW2000 size exclusion column equipped with UV detector at 
232 nm with an injection volume of 20 μL using 150mM pH 6.9 NH4Ac, as mobile 
phase. The SEC column had V0 = 2.3 mL (by DNA injection), and Vt = 5.4 mL (by 
acetone injection). The calibration curve (log Rh vs Ve) for the TOSOH SW2000 column 
was constructed using protein standards of thyroglobin (Rh = 7.9 nm), antithombin (Rh = 
3.9 nm), bovine serum albumin (Rh = 3.5 nm), ovalbumin (Rh = 3.0 nm), β-lactoglobulin 
(Rh = 2.6 nm), carbonic anhydrase (Rh = 2.3 nm), ribonuclease A (RH= 1.8 nm), and 
cytochrome C (Rh = 1.6 nm). The universal log RH vs Ve curve
89
 was converted to the 
heparin calibration curve (log Mw vs Ve) by using an RH-Mw relationship for heparin 
based on measurements for various heparin Mw fractions
10
 and diffusion coefficients (DT 
= 6πη RH/kBT) in reference 10. 
2.4 Results 
Several important features appear in Figure 2.1A, which shows superimposed 
electropherograms of native heparin and Tinzaparin.  (1) The electropherogram of native 
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heparin was abruptly truncated at µ = 4.7 x10
-4
 cm
2 
V
-1
 s
-1
 in a manner uncorrelated with 
the shape of the molecular size (SEC) distribution in Figure 2.1B. This result is consistent 
with limitations due to diminution of effective charge by counterion condensation for 
polyelectrolytes with >1.
55
 However, the limiting mobility is remarkably high: a search 
of the literature
58,63,84,90
  produces only one report  of a mobility
91
 as high as our result for 
µL
∞ 
 of  heparin. (2) Mobilities of the oligomers (dp ≤ 20) are even larger than the 
limiting value for native heparin. The SEC chromatograms show the expected level of 
overlap of molecular size distributions in that roughly 1/3 of the mass of heparin is within 
the MW range of Tinzaparin. Nevertheless, nearly 70 % of the species in Tz display 
larger values of mobility than any native heparin components, i.e. µ> 4.7 x10
-4
 cm
2 
V
-1
 s
-
1
. 
 
 
 
 
 
 
 
 
1.  
Figure 2.1: Comparison of native heparin (black) and low-MW heparin 
(Tinzaparin, Tz) (blue). (A) Electropherograms obtained at 10 mM phosphate 
buffer at pH 6.8 (detection at 200nm). (B) Size exclusion chromatograms of native 
heparin and tinzaparin on TOSOH SW2000 column in 150 mM Ammonium acetate, 
pH 6.9 (detection at 232 nm). 
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The appearance of well-resolved species at one end of the distribution of 
mobilities, and also at one end of the distribution of sizes prompted us to consider a 
hypothetical correlation between small size and high mobility for Tz species (vide infra). 
While a similar correlation was noted for olgiomers of PSS
58,84
 and acrylic acid,
92
 no 
physicochemical explanation for such common behavior of linear PE oligomers has been 
offered. The striking observations are thus (1) the high mobilites for native heparin, 
nevertheless abruptly truncated at µ = 4.7 x10
-4
 cm
2 
V
-1
 s
-1
; and (2) the even higher 
mobility of Tz oligomers, as if they were not subject to counterion condensation. We will 
show later that different structural features within heparin lead to these two effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Qualitative comparison of the shapes of distributions from capillary 
electrophoresis and mass spectrometry for dp 20. A) The electropherogram of 
heparin dp20 (1 g/l) in 10 mM phosphate buffer, pH 6.8.  B) Mass spectrum of dp20 
obtained at -5 charge states using FT-ICR MS (buffer: 50:50 MeOH: H2O with 10 
mM ammonium acetate) 
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The electropherogram and mass spectrum of dp 20 in Figures 2.2A and 2.2B 
make it possible to compare mobility and mass distributions. Mass distributions could be 
recognized as distributions of sulfation levels: all signals correspond to dp20 chains 
having in common the components shown in Figure 2.3 with R1 and R2 groups 
designating variations due to post-polymerization enzymatic modification. Mass 
spectrum showed the number of SO3H in dp20 ranges from 22 to 29. While the 
distribution of mobilities is truncated at µ = 4.9 x10-4 cm
2 
V
-1
 s
-1
 in CE, the distribution of 
sulfation is somewhat symmetrical in MS; therefore we can suggest that the most highly 
sulfated oligomers (1.5 sulfates per saccharide on average) eluting at the leading edge of 
the electropherogram. It was obvious that the truncation of the mobility for dp20 arises 
from the same effect demonstrated for heparin in Figure 2.1A.  
 
 
Figure 2.3: Representation of heparin structure 
 
The behavior of the oligomeric components seen in Figure 2.1A was explored 
using size-fractionated oligoheparins that are monodisperse with respect to chain length 
(dp). The breadth of the electropherogram for dp 20 in Figure 2.2A is attributable to 
sulfation, variable with respect to sequence arrangement and degree (sulfates per 
saccharide repeat unit, DS). A leading edge for dp20 in  Figure 2.2 at µ = 4.9 x10
-4
  cm
2 
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V
-1
 s
-1
 is seen as well for dp 6,8 and 10 in Figure 2.4; the mass spectra for these, while 
insensitive to sequence arrangement, show that these leading edges can be assigned to the 
highest average sulfation level, DS = 1.5. For this reason, we use the leading edge 
mobility µmax to establish chain length dependence, i.e. at constant DS = 1.5. Figure 2.4A 
shows the dramatic effect of chain length on mobility, as anticipated from Figure 2.1A, 
focusing on the DS = 1.5 components. Table 2.1 summarizes molecular weight, contour 
length L and µmax for heparin and also incorporates comparable results for oligomers of 
sodium poly(styrenesulfonate) (to be discussed below). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: A) The electropherograms of heparin oligomers (1 g/L) at 10 mM 
phosphate buffer, pH 6.8 B) Individual mass spectrum of heparin oligomers (dp6, 
dp8, dp10) at +2 charge states (Buffer: 10 mM ammonium acetate, pH 6.8). (X, Y, 
Z) represents degrees of polymerization, number of sulfate groups and number of 
acetyl groups, respectively.  
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Table 2.1: Mobility versus contour length for heparin oligomers and NaPSS  
Heparin NaPSS
d
 
 L
a
 (nm) μ max (10mM)  
Mw,  x10 
-3
 
g/mol L
c
( nm) 
μ max (40mM) 
 
μ max (10mM) 
 
dp4 2
 b
 5.3
b
 1.6 2.4 4.72 5.3±0.3 
dp6 3 5.2 5.4 8 4.48 5.1±0.3 
dp8 4 5.1 12 18 4.25 4.7±0.3 
dp10 5 5.1 35.2 52 4.20 4.26 
dp20 10 4.9 70 104 4.28 4.26 
native 24 4.7 88 131 4.22 4.26 
 44 4.7 250 372 4.20 4.26 
 65 4.7 500 744 4.20 4.26 
 a: Disaccharide length 1nm
10
 
b: From tinzaparin electrophoregram.   
c: NaPSS repeat unit contour length 0.25 nm 
d: Data for 4 0mM is taken from reference 85. The data for 10 mM is calculated using 
values in reference 58 and 84. Contour lengths calculated as Mw/m0 , where m0  is the 
residue mass corrected for degree of sulfonation.  
2.5 Discussion 
Data from Table 2.1 for dp6-20, presented in Figure 2.5 show that µmax varies 
inversely with log L, converging on µL
∞
 for native heparin (dotted line). The mobility of 
dp20 coincides with the electrophoretic front of native heparin (Figure 2.1A), because 
counterion condensation in both cases determines the maximum possible mobility. In 
order to establish the generality of this effect, we plot in the inset of Figure 2.5 similar 
data for oligomers of sodium poly(styrenesulfonate) (PSS), both as the values given in 
reference 85 at 40 mM salt, as well as values extrapolated to 10 mM salt using the salt-
dependences  in references 58 and 84. With either data set, PSS mobility decreases with 
increasing chain length, reaching µL
∞
 ~ 25 nm, very close to the behavior for heparin, 
although µL
∞
 shows a significant 10% diminution relative to heparin. Overall, Figure 2.5 
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suggests a fundamental relationship between contour length and mobility independent of 
structural detail. We note that the monotonic behavior of µL seen in Figure 2.5 does not 
persist for PE oligomers below L = 2 nm.
58,84
 Such small molecules, not subject to 
counterion condensation, and with complex frictional properties, should not be viewed as 
members of the apparently homologous series of heparin dp6-20 and their behavior is 
beyond the scope of the present study. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Leading edge mobility µmax versus contour length for heparin oligomers 
(dp4-dp20) of DS = 1.5, and limiting value for native heparin (red dotted line). The 
open square is used to indicate that the mobility of dp4 was taken from the 
tinzaparin electropherogram (Figure 2.1A). Inset: Mobility vs. contour length for 
poly(styrenesulfonate) (PSS) measured at 40 mM, from ref 85, and the calculated 
mobilities for 10 mM, using the experimental PSS mobility data for various ionic 
strengths from refs 58 and 84.  Arrows indicate the contour length at which the 
limiting mobility is reached. 
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We calculate from structure that the mean dimensionless structural linear charge 
densities  for Hp (2.84) and 80 % sulfonated  NaPSS,  (2.25) are essentially independent 
of chain length, so that explanation of the L-dependence of Figure 2.5 must be sought 
elsewhere. While relationships between friction coefficient and chain length have been 
proposed,
93
 it is difficult to understand why that effect would truncate at a common 
length for different polyelectrolytes. For this reason, we turn to the L- dependence of the 
effective value of , i.e. the charge density after counterion condensation.  
Explanation of these observations appears in a recent treatment of end effects on 
eff for oligopolyelectrolytes.
87
 In brief, the electrostatic potential arising from a sequence 
of neighboring polyelectrolyte units responsible for counterion condensation must be 
diminished at the sequence termini, e.g. at chain ends. The increasing fraction of terminal 
sulfate groups with decreasing dp is then responsible for the reduced counterion 
condensation. This is equivalent to a monotonic increase in eff for shorter chains and 
accounts for the remarkably high mobilities noted for dp 4-10 in Figures 2.1A and 2.5.  
The equilibrium value of the effective charge fraction f(s) for any segment along 
the length of a polyelectrolyte oligomer with univalent counterions is given by;
87
 
)/ln(
)ln(
1(
2
1
)(
bs
b
sf   Eq. 2.2 
where κ is the inverse of the Debye screening length,  s the distance from the end, b the 
axial spacing between neighboring charged groups, and ξ the dimensionless charge 
density parameter: 
b
l
Tbk
e
b
B
4
2
   Eq. 2.3 
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Here, e is the electron charge, ε the permittivity of the solvent, kB the Boltzmann 
constant, and lb the Bjerrum length. In order to calculate the effective charge fraction for 
heparin oligomers, each disaccharide is assumed to have the same average number of 
charges, 4 per disaccharide (three sulfates and one carboxylate, viewed identically 
because the carboxylate is fully ionized at pH 6.8).  With a length of 1 nm per 
disaccharide, b = 0.25 nm and ξ = 2.84. Figure 2.6 shows the way in which heparin 
structure is represented in a form consistent with Eq 2.2 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Representations of an average heparin structure. Above:  molecular 
structure of the heparin disaccharide unit. Below: representation adopted for 
implementation of Eq.2.2: each disaccharide is represented by four segments with 
one charge apiece. Actual disaccharide length is 1 nm,
10
 average distance between 
charges b (segment length) is 0.25 nm.  
 
 
These resultant values of f(s) are averaged over the values of s for each oligomer 
chain to give the mean effective charge fraction fav in Table 2.2. The effective charge 
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fraction was calculated at each charge sites and summed over the entire length of the 
oligomer, which gives the total effective charge of the oligomer. This effective charge is 
then divided by the total number of charge sites to get average f(s). For small oligomers 
(dp8 and below) fav/L decreases rapidly with L because condensation effects propagate 
only 0.2κ-1 (~0.5 nm) from the ends. The minimum value for fav (full condensation) 
approached asymptotically at high L is 0.3. The lower mobilities of NaPSS relative to Hp 
in Figure 2.5 (about 10% less) can now be understood as a consequence of its lower 
effective charge density fav/b. These lower effective charge densities arise from its 
structural charge density 1/b which is 26% lower than that of Hp. This result, µHp/µPSS ~ 
1.1 is observed even in the limits at high MW. Interpolating the results of Cottet et al.,
84
 
for the ionic strength dependence of high-MW (88% sulfonated) PSS mobility to I = 10 
mM leads to an identical result of µHp
∞/µPSS
∞
 = 4.7/4.2. Most importantly, Table 2.2 
clearly shows the dramatic increase in the mean segment effective charge with decreasing 
chain length as was seen in Figure 2.5.  
 
Table 2.2: Calculated effective charges and charge fractions of heparin oligomers 
and NaPSS at I = 10 mM  
Heparin NaPSS 
L(nm) 
Total 
Qstructural 
Total 
Qeffective fav L (nm) 
Total 
Qstructural 
Total 
Qeffective fav 
2 8 6.8 0.85 2.4 8 7.2 0.91 
3 12 8.7 0.72 8 25 15.4 0.62 
4 16 10.3 0.64 18 57 27.9 0.49 
5 20 11.8 0.59 52 167 66.3 0.40 
10 40 18.7 0.47 104 333 120.4 0.36 
24 96 35.6 0.37 131 419 147.7 0.35 
44 176 58.1 0.33 372 1190 383.6 0.32 
    744 2381 735.8 0.31 
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Figure 2.7: Contour length dependence of the leading-edge mobilities for heparin 
oligomers (dp4, dp6, dp8, dp10, dp20 and native heparin limiting value) compared 
to theoretical average effective charge (dashed line). Positions of the two vertical 
axes are arbitrary. Inset: Dependence of mobility on theoretical effective charge per 
segment length for Hp (○) and NaPSS (Δ). 
 
  Figure 2.7 shows that the contour length dependence of measured mobilities 
from Figure 2.5 closely resembles the contour length dependence of fav calculated from 
Eq. 2.2 (dashed line). This result reflects the interdependence of µ and fav, which is shown 
in the inset, although the arbitrary nature of the two ordinate axes limits the interpretation 
of the apparent congruence of experiment and theory. Further evidence for a fundamental 
basis for this relationship comes from the nearly congruent data for heparin and PSS, at 
least in the region of intermediate chain length.  The difference between these two 
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polyelectrolytes with respect to limiting mobilities will be discussed below. Regardless of 
this difference, µL
∞
 = 4.7 x10
-4
 cm
2 
V
-1
 s
-1
 -- for heparin at large L -- is a condensation 
barrier: chains in excess of L = 20 nm are subject in principle to full condensation. This 
barrier is the basis for the truncated electropherogram of native heparin in Figure 2.1A, 
and for the leading edge of the electropherogram for dp20 in Figure 2.2A. With further 
decrease in L, components of lower degrees of sulfation escape this barrier, leading to the 
more complex electropherograms in Figure 2.4A. The different levels of sulfation for 
dp6-10 are relatively few in number: the complexity of those electropherograms largely 
reflects different sequence arrangements
94
 that are not distinguishable in the mass spectra, 
see Figure 2.2B.  
While the end effect explains the dependence of mobility on L for heparin 
oligomers, it is necessary to consider the difference in structural charge densities for 
heparin and PSS in order to compare those polyelectrolytes. Data for PSS and heparin are 
normalized in the inset of Figure 2.7 by multiplying fav by the mean structural linear 
charge density, 1/bav. The congruence of results for heparin and PSS in the inset for 
5<L<20 nm strongly suggests that the effective linear charge density fav/b is the main 
determinant of mobility in the region of intermediate chain lengths. 
The convergence of µ as a function of (fav/b) for heparin and PSS in the inset of 
Figure 2.7 does not extend to full-length chains inasmuch as the limiting values for 
heparin and PSS at L>25 nm (low fav/b here) are 4.7 and 4.2, respectively. This might 
reflect differences between heparin and PSS in the value of the friction coefficient per 
segment (F). Inverse dependence on L is seen both for the effective charge per heparin 
charge site obtained from Eq 2.2, and for the friction per PSS segment obtained from 
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simulations.
93,95
  However, the variation of the latter in the relevant range of L is small
93
 
compared to the variation of fav. Consequently, µ ~ fav/F should increase with L, opposite 
to our results in Figure 2.7.  Thus, the lower mobility for PSS vs heparin at L>25 nm 
cannot be due to a difference in monomer friction coefficients.  These simulations for 
PSS also show that the value  of Lµ
∞
 at which the charge per monomer becomes constant 
is larger than the value of L at which F becomes constant,
93
 i.e. the charge effect 
propagates further from the chain ends than the friction effect. 
The value of µL
∞
 = 4.7 x10
-4
 cm
2 
V
-1
 s
-1
 for heparin is not only larger than for 
PSS, and even exceeds values (µ< 4.2
63,90
) reported for other polyelectrolytes at this ionic 
strength. To explain the anomalously high values for PSS and especially heparin, we 
consider a common feature of both polyelectrolytes, their non-uniform linear charge 
sequences.  Here, PSS was prepared by sulfonation of low MWD polystyrene which 
results in charge distribution of sulfonation sequence. Similar to the variety of sulfation 
sequences in heparin, this could lead to intrachain sequences of low charge, especially at 
large L. Reduction of condensation for a charged segment at a junction with a neutral 
sequence
87
 is a natural extension of the diminution of condensation on chain ends. For 
heparan sulfate HS, a near cousin of heparin, such low- and high-sulfation domains (NA 
and shorter NS domains) are understood to be somehow related to the remarkable breadth 
of growth factors whose activities are modulated by HS.
22,38,96-100
 NS segments at NA/NS 
interfaces are thus subject to reductions in counterion condensation. Such junction effects 
are expected to be minimal for PSS oligomers, the likelihood of a charged segment 
having an uncharged neighbor being only 20%, and the congruence of PSS with 
intermediate length heparin oligomers in the inset of Figure 2.7 suggests that they are not 
35 
 
significant for heparin either. However, it does seem likely that junction effects could be 
responsible for the remarkably high electrophoretic mobility of native heparin compared 
to e.g. synthetic polyelectrolytes with higher structural charge densities.
59
  
The application of this model to native heparin is beyond the scope of the present 
work, but it is of interest to note that the more biologically functional HS is known to 
have sequences of high and low sulfation (NS and NA domains) whose arrangement 
appears to be strictly regulated.
5,101
 While the precise role of NS and NA domains in 
growth factor binding is the subject of debate,
2,20,22
 it is worth pointing out that the 
dimensions of the positive “heparin-binding domain” identified on the typically net-
negative heparin-binding proteins is similar to the dimensions of the NS domains of 
heparin sulfate.
38
 These domains comprising 2-8 heavily sulfated saccharides, are 
characteristically bracketed by NA domains.
97
 Thus, junction effects could preserve the 
high effective charge density of NS domains by inhibiting counterion condensation.  On 
the other hand, it has been proposed that heparin-protein binding is analogous to DNA-
oligolysine interactions, in the sense of being driven by the entropy of expelled 
counterions,
49,70
 in which case an increase in the effective charge of the protein-binding 
domain on HS could amplify the binding constant.   At this point, it can only be 
suggested that examination of NA/NS domains take into account to relationship between 
sulfation patterns and counterion density. 
2.6 Conclusions 
The truncated electropherogram for native heparin, highly skewed in comparison 
to either distributions of molecular size or degrees of sulfation, is best explained by a 
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limiting effective charged density arising from counterion condensation. For a partially 
cleaved heparin, some oligomers “escape” this counterion condensation limit, in 
agreement with the mobilities µ obtained from well-defined heparin oligomers, which 
show inversed dependence of mobility on chain length L. The µ vs L relationship is 
remarkably similar for oligomers of both heparin and the partially sulfonated PSS; 
heparin however exhibits ~10% larger limiting mobility value (µHp
∞/µPSS
∞
 = 4.7/4.2). A 
theoretical treatment for polyelectrolyte end effects shows the reduced counterion 
condensation, i.e. larger effective charges (fav) for short chains, accounting for the inverse 
relationship between µ and L for both heparin and PSS. In addition to the end segments, 
junctions separating regions of different charge densities could lead to diminishing 
counterion condensation,
87
 and this effect could be more pronounced for heparin due to 
its higher degree of heterogeneity.  
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CHAPTER 3 
 
A HEPARIN DECAMER BRIDGES A GROWTH FACTOR AND AN 
OLIGOLYSINE BY DIFFERENT CHARGE-DRIVEN INTERACTIONS 
Minsky, B. B.; Nguyen, T. V.; Peyton, S. R.; Kaltashov, I. A.; Dubin, P. L. Heparin 
decamer bridges a growth factor and an oligolysine by different charge-driven 
interactions. Biomacromolecules 2013, 14, 4091-4098. 
3.1 Abstract   
Full-length heparin is widely used in tissue engineering applications due its 
multiple protein-binding sites that allow it to retain growth factor affinity while 
associating with oligopeptide components of the tissue scaffold. However, the extent to 
which oligopeptide coupling interferes with cognate protein binding is difficult to predict. 
In order to investigate such simultaneous interactions, we examined a well-defined 
ternary system comprised of acidic fibroblast growth factor (FGF), tetralysine (K4), with 
a heparin decamer (dp10) acting as a non-covalent coupler.  Electrospray ionization mass 
spectrometry was used to assess binding affinities and complex stoichiometries as a 
function of ionic strength for dp10-K4 and FGF-dp10. The ionic strength dependence of 
K4-dp10 formation is qualitatively consistent with binding driven by the release of 
condensed counterions previously suggested for native heparin with divalent 
oliogpeptides (Mascotti, D. P.; Lohman, T. M. Biochemistry 1995, 34, 2908-2915). On 
the other hand, FGF binding displays more complex ionic strength dependence, with 
higher salt resistance. Remarkably, dp10 that can bind two FGF molecules can only bind 
one tetralysine. The limited binding of K4 to dp10 suggests that the tetralysine might not 
block growth factor binding, and the 1:1:1 ternary complex is indeed observed. The 
38 
 
analysis of mass distribution of the bound dp10 chains in FGF·dp10, FGF2·dp10 and 
FGF·dp10·K4 complexes indicated that higher degrees of dp10 sulfation promote the 
formation of FGF2·dp10 and FGF·dp10·K4. Thus, the selectivity of appropriately chosen 
short heparin chains could be used to modulate growth factor sequestration and release in 
a way not feasible with heterogeneous native heparin. In support of this, human 
hepatocellular carcinoma cells (HEP3Bs) treated with FGF-dp10-K4 were found to 
exhibit biological activity similar to cells treated with FGF.  
3.2 Introduction 
Glycosaminoglycans (GAGs) such as heparin (Hp) are incorporated into tissue 
engineering scaffolds with the intention of mimicking their ability in the extracellular 
matrix (ECM) to sequester and release numerous growth factors (GFs).
7,33,68,99
 Effective 
assembly strategies accomplish this through specific and non-specific association of 
GAGs with matrix components such as peptides. Model ternary systems can facilitate in 
vitro investigation of simultaneous complex formation among glycosaminoglycans, 
growth factors and scaffold elements, revealing how non-covalent e.g. electrostatic, 
interactions can be utilized. Combination of growth factors with peptide and GAG 
components of reduced heterogeneity is currently necessary in order to analyze these 
ternary systems with powerful characterization techniques such as electrospray ionization 
mass spectrometry (ESI-MS). 
GF-binding heparinoids have been coupled to scaffold polymers in order to 
achieve modulated release of the protein either with or without heparin. The covalent 
attachment of heparin to scaffolds has been pursued through many strategies
102-109
 which 
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may obstruct GF binding sites or introduce toxic cross-linking agents.
110
 This is avoided 
by means of oligopeptide scaffold components that bind heparin non-covalently.
108,110-113
 
The scaffold structure and Hp-oligopeptide affinity determine the release rate of Hp-
GF.
110,111
 The strength of the heparin-GF bond determines both the rate of GF release and 
whether it is released along with bound Hp. It is therefore important to consider whether 
differences in the nature of two interactions allow them to be independently modulated 
by either ionic strength or heparin microstructure.  
The model used here for the binding of oliogpeptides to heparin originates from 
the counterion condensation theory of Manning,
54,55
 initially developed to describe the 
binding of oligolysines to DNA.
47,70
 In the oligolysine-DNA case, the driving force is the 
entropy of the release of DNA counterions (Na
+
) from the condensed layer. This leads to 
a particular form of the ionic strength dependence of the binding constant: - log Kobs ~ n 
log I, where Kobs is equilibrium association constant, I is ionic strength and n is ligand 
charge.  Lohman and Mascotti
49
 applied this concept to oligopeptide/heparin binding 
(conceptually replacing DNA with heparin) and measured the salt dependence of the 
binding constants. Finding linearity of log Kobs vs. log I for heparin and cationic 
oligopeptides, they concluded that the measured G obs was purely entropic. This 
observation, along with recent direct measurement of counterion condensation by 
heparin,
114
 provides strong evidence for the release of condensed counterion during the 
binding of cationic ligands to heparin. However, further extension of the Manning-
Record model in which the oligopeptide has been replaced by a protein
17,115,116
 has since 
been questioned on the basis of fundamental uncertainty regarding the expanded role of 
long-range interactions.
48
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While non-covalent coupling of growth factors to Hp is recognized as a valuable 
approach for the development of bio-functional tissue surrogates, questions arise about 
“electrostatic” heparin-oligolysine binding vs “specific” Hp-GF interactions.  The former 
has been widely accepted as non-specific, but the precise nature of the latter has remained 
controversial. Models based on the definition of Hp-GF as a cognate system emphasize 
“specific”, i.e. short-range forces comprising hydrophobic and pair-wise interactions (H-
bonding and salt bridges).
117-120
 These are thought to impose on heparin precise structural 
and/or conformational requirements for protein recognition. However, there is increasing 
evidence that strong binding occurs between globally negative heparin-binding proteins 
and polyanions,
45
 especially when polyanion charge distributions are arranged in a way 
that minimizes long-range repulsion while optimizing short range attractions with locally 
positive protein domains.
31,51,121
 This can result in a level of selectivity that does not arise 
from short-range interactions such as hydrogen-bonding or “ion-pair” formation.9,45 
Supporting this perspective, recent findings indicate that various FGFs share the same 
GF-binding sites on HS,
16,21
  where binding affinity is correlated with the extent of 
sulfation.
21
  Catlow et al. showed that the interaction of hepatocyte growth factor/scatter 
factor with HS is dominated by electrostatics inasmuch as sulfate density as opposed to 
the presence of particular types of sulfation affects the selectivity.
34
 Thus the interactions 
considered here could be intrinsically promiscuous
20,35
 and dominated by columbic 
forces. There is also growing evidence that these interactions can be highly 
selective.
122,123
 
When Hp-GF interactions are viewed in the context of the vast array of 
polyelectrolyte-protein interactions,
44
 the role of ionic strength is to diminish long-range 
41 
 
electrostatic interactions between Hp and complementary protein positive “patches,”44 an 
effect typically parameterized by the Debye-Hückel screening length  
-1
. 
9,28,51,124
 The 
possible role of long-range interactions also leads directly to consideration of long-range 
repulsion between Hp and the negatively charged domains of many of its morophogen 
cognates,
125
 an additional issue when the oligocationic “ligand” in the Record-Manning 
model is envisioned as part of a protein that may be larger than its heparinoid “host”. 
The differences in the effects of both Hp microstructure and ionic strength on the 
two types of interactions could make it possible to control the relative strengths of Hp-GF 
and Hp-oligopeptide interactions either by using appropriate heparin fractions, or by 
adjusting salt concentration. Hp microstructure, difficult to define for the immensely 
heterogeneous native heparin, can be better identified using GF-specific oligoheparins. 
The length of such oligoheparins must be sufficient to allow for non-covalent binding to 
both scaffold oligopeptide units and growth factors. Competition between oligopeptide 
and GF for the heparin chains could then be modulated if the two types of binding are 
driven by different mechanisms, e.g. counterion release for the former and the screened 
electrostatics for the latter. These differences could make it possible to tune the two 
interactions so that binding of oligopeptide and GF could take place simultaneously.  In 
theory, end effects on counterion condensation by heparin oligomers
87
 suggest that the 
central saccharide units, rich in condensed counterions,
114
 could provide unique sites for 
Record-Manning type oligolysine binding, leaving the distal heparin units available for 
screened GF binding, i.e. suppressed at length scales larger than the Debye length, 
-1
 
(nm) ≈  0.3 I -1/2 in 1:1 electrolyte. 
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The model system studied in this work allows for in vitro investigation of 
simultaneous complex formation among low MW GAGs, GFs and scaffold peptide 
elements. The mechanism of ternary and binary complex formation involving these 
species could contribute to molecular level understanding of the assembly of scaffolds 
and their ultimate behavior in cell culture. A specific hypothesis to be tested is that the 
GF binding sites within a given chain have unique sulfate charge densities. Elucidation of 
protein “recognition sites” on heparin has been pursued by crystallography, typically 
involving assumptions about certain pair-wise interactions not directly related to sulfate 
charge densities.
23,126
 
In this work, ESI-MS is applied to determine the stoichiometry and ionic strength 
dependences for a ternary model system comprising FGF-1, a heparin decamer (dp10) 
and tetralysine (K4). ESI-MS of native state proteins has recently evolved as a very 
important tool to detect their non-covalent complexes, revealing compositional details of 
the ligand-protein complexes.
88,127,128
 Increased sensitivity, low sample requirements and 
applicability to transient complexes have improved the importance of native ESI-MS.  
We examined the effects of ionic strength on the FGF-1-dp10 and K4-dp10 interactions, 
and found the latter but not the former to be analogous to the well-known oligolysine-
oligonucleotide electrostatic model.
48,70
 Furthermore, our results indicated that the ability 
of the components of dp10 to engage in the ternary complex or bind multiple growth 
factors depends on their sulfation levels. 
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3.3 Experimental 
3.3.1 Materials  
Heparin decasaccharide (dp10), prepared by high-resolution gel filtration of 
partial heparin lyase digestion of high quality heparin, was generously donated by Prof. 
John Gallagher from Iduron (Manchester, UK). Acidic fibroblast growth factor (includes 
His to Gly 93 mutation to increase stability,
129
  pI = 7.8) was provided by Prof. Robert 
Linhardt (RPI, Troy, NY).   Tetralysine (K4) was purchased from Sigma.  
3.3.2 Methods.  
3.3.2.1 Mass Spectrometry 
All experiments were performed with a QStar-XL hybrid quadrupole-time-of-
flight MS equipped with a nano-ESI-source (AB Sciex, Toronto, Canada). The 
measurements were performed using closed (2 μm id) glass nanospray capillaries (New 
Objective, Woburn, MA). FGF-dp10 binding experiments were acquired using following 
settings of ion optics in the ESI interface:  DP: 100, FP: 265, DP2: 15. K4 and dp10 
binding experiments were performed utilizing mild ion desolvation conditions (DP: 40, 
FP: 150, DP2: 15). FGF-1 was buffer exchanged using Amicon (10kDa cut off) with 100 
mM NH4CH3CO2, and the protein concentration was verified by UV-VIS using molar 
absorptivity of 17545 M 
-1
 cm 
-1
. FGF, dp10 and K4 were diluted from the stock solutions 
to the final concentrations (2 μM, 3 μM and 10 μM, respectively) in the desired 
ammonium acetate concentrations. ESI-MS was used to determine stoichiometries of 
FGF-1-dp10 complexes, and m/z values of the protein and the complexes were assigned 
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with BioAnalyst v1.1.5 (MDS Sciex/Applied Biosystems, Toronto, Canada). The mass 
distribution of the protein-bound heparinoid molecules were calculated using the 
following formula: 
FGF
nMmHz
z
m
  Eq.3.1 
where n represents total number bound FGF-1 molecules, m is the total protons attached 
and MFGF is the mass of a single FGF molecule. Since all analyses were performed in the 
positive ion mode, it is expected that each ionic species will also contain 4-5 cations 
(NH
4+
). Shaded boxes are used in Figure 3.3 and 3.5 to indicate the mass ranges for 
heparinoid species with different extent of sulfation (the overlap is due to the uncertainty 
in the number of cationizing agents attached to each polyanionic chain).   
3.3.2.2 Computational 
DelPhi V. 4r1.1,
130,131
 which applies non-linear Poisson-Boltzmann equation to 
generate the potential surface of the protein, was used to model the electrostatic potential 
around FGF-1 (PDB id: 1K5U) and heparin decamer (Solution NMR: 1HPN). The 
structures were taken from the protein data bank (http://www.rcsb.org/).  The charges of 
amino acids on the protein were determined using the spherical-smeared charged model 
put forward by Tanford.
132
 
3.3.2.3 Cell Culture and Proliferation Assays 
All cell culture supplies were purchased from Life Technologies, Carlsbad, CA, 
unless otherwise noted. Human hepatocellular carcinoma cells (HEP3Bs, American Type 
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Culture Collection, Manassas, VA) were cultured in modified Eagle's medium (MEM) 
supplemented with 10% Fetal Bovine Serum (FBS) and 1% penicillin-streptomycin (P/S) 
at 37 oC and 5% CO2.  To quantify cell growth in response to growth factors and growth 
factor complexes, HEP3Bs were seeded at 10,000 cells/well in 96-well plates (Corning, 
Tewksbury, MA), in standard growth medium. After 24h, the medium was replaced with 
the serum-free medium containing 1% P/S and either fibroblast growth factor (FGF) or 
FGF.dp10.K4, ranging from 0 to 50 ng/mL.  We used the CellTiter 96 AQueous One 
Solution Cell Proliferation Assay (Promega, Madison, WI) to measure cell proliferation 
at 24 h and 72 h. After 3 h of incubation, the absorbance was read at 490 nm with a 
BioTek ELx800 microplate reader (BioTek, Winooski, VT). 
3.3.2.4 Statistical Analysis 
One-way ANOVAs were performed with using Prism v5.04 (GraphPad Software, 
La Jolla, CA), the Tukey post-test was used to determine significance of pairwise 
differences. Data are reported as mean ± standard error with N = 3. P ≤ 0.05 is denoted 
with *, ≤ 0.01 with **, and ≤ 0.001 with ** 
 
 
 
 
46 
 
3.4 Results and discussion 
3.4.1 K4 binding to dp 10 
 
 
 
 
Figure 3.1: (a) ESI mass spectra of dp10 (3 µM) and K4 (10 µM) in pH 6.8 
ammonium acetate at varying ionic strengths. Not shown: free K4 (m/z = 531, z = 
+1). (b) ESI mass spectra of FGF-1 (2 μM) and dp10 (3 μM) in 100, 250, 400, 550 
and 1000 mM ammonium acetate. The shaded columns represent (a) dp10 and 
dp10·K4; (b) FGF, FGF·dp10 and FGF2·dp10. 
  
Figure 3.1 shows the effect of ionic strength on the binding of dp10 at pH 6.8 to 
K4 (a) and to FGF (b). Even though K4 is in molar excess (10:3 K4:dp10), K4 forms only a 
1:1 complex with dp10. This is in contrast to the ability of dp10 to bind at least two FGF 
molecules.  Furthermore, the contour length of dp10 (5 nm) is significantly larger than 
that of K4 (~ 2 nm).  It appears that the binding energy for the second K4 is diminished, 
i.e. binding is apparently anticooperative. Arguments based on variations in local 
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sulfation would not explain why there are no dp10 chains that bind two oligolysines. We 
therefore explore the  earlier studies of oligolysines and heparin, which supported the 
model put forward by Manning and Record.
46
 As noted above, these studies showed that 
the driving force for oligocation binding to polyanion (e.g. DNA) is the entropy of the 
release of the polyanion’s counterions from its condensed layer. A more recent 
theoretical result by Manning for oligo-polyelectrolytes  is the diminution of 
condensation at and near chain ends,
87
 subsequently verified by Minsky et al. for heparin 
oligomers.
114
 Representation of the heparin disaccharide structure (Figure 2.6, above) 
neglecting positional variations of sulfation leads to visualization of the chain as treated 
in the condensation model (Figure 2.6, below), with the condensed counterion layer 
depleted at chain ends. If those ions are involved in the oligolysine binding process, the 
strongest K4 binding site would comprise chain units far from the ends of dp10, i.e. 
saccharides 3-8 (contour length ~3 nm).  The remaining distal regions are incompetent 
binders with respect to both length (1 nm) and condensed counterions. To further 
examine the applicability of this model, we examine whether the strong binding 
suppression with an increase from 40 to 150 mM ionic strength in Figure 3.1(a) is 
consistent with the condensed counterion model.   
In order to compare dp10-K4 results to those in the highly influential Mascotti and 
Lohmann paper,
47,49
 it was necessary to extrapolate from the binding constants, Kobs, 
which were obtained in refs. 30 and 32 for native heparin with a +2 oligolysine (n =2). 
While their study
49
 only covered a narrow range 12 < I < 30 mM, they obtained Kobs  ~ I 
-2 
in agreement with theory in which the number of released counterions is equal to the 
ligand charge ( - (dlogKobs / dlogI ) = n ),
46
 subsequently supported by Manning et al.
48
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With n = 4, Kobs is expected to exhibit I 
-4 
dependence for K4. Thus, the dramatic 
suppression of binding seen in Figure 1(a) for the ca. 4-fold increase in I from 40 to 150 
mM is entirely consistent with the 200-fold ((ca. 40/150)
-4
) decrease in Kobs  as predicted 
by theory, suggesting that the binding of K4 to dp10 is driven by the release of condensed 
counterions. The remarkably different I dependence in Figure 3.1(b) shows that a 
different mechanism must drive the binding of FGF to dp10 at 400 mM; binding based on 
the displacement of condensed counterions  is not possible when the bulk ionic strength 
exceeds 380 mM, the local concentration of condensed counterions for heparin.
48
   
3.4.2 FGF binding to dp10 
In order to compare binding strengths for FGF-dp10 vs K4-dp10, the former was 
also investigated using salt concentration as a surrogate for binding affinity. Figure 3.1 
(b) shows the formation, in pH 6.8 ammonium acetate, of 1:1 and 2:1 complexes of FGF-
dp10 at I = 100, 250, 400 mM. If we use the salt resistance of complex formation as a 
measure of binding affinity, we find that the FGF-dp10 1:1 complex is more stable than 
the K4-dp10 complex (see Figure 3.1), and also the FGF-dp10 2:1 complex. However, 
even the FGF-dp10 1:1 complex is fully suppressed at I > 550mM, indicating the role of 
screened electrostatics. Although the pH used is only moderately lower that the pI, the 
charge distribution is anisotropic leading to a discernible positive domain (Figure 3.2).  
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Figure 3.2: FGF-1 (PDB id: 1K5U) electrostatic images for pH 7.0 and I = 400 mM, 
550 mM and 1000 mM. 5 Å surfaces (magnitude of charge shown by color intensity, 
blue positive, red negative), and equipotential surfaces (grids) +0.2 kT/e and -0.2 
kT/e. The heparin decamer (Solution NMR id: 1HPN) is drawn to scale to help 
visualize its ability to reside within the FGF positive domain (sulfate groups are 
shown in yellow). The pH differences between Figure 3.1 (b) and the DelPhi 
calculations have no significant effect on the aminoacid charges 
 
Calculations of screened electrostatics by DelPhi have been recognized as a 
quantitative tool for elucidating the electrostatic binding energy of  both protein-
polyelectrolyte
50
 and protein-protein interactions,
133
 and comparisons with experimental 
results are facilitated by the display of electrostatic potential contours. The potential 
contours represented as grids in the DelPhi images arise from the conjoint sum of all 
possible pair-wise coulomb forces that are subjected to the moderating influence of the 
ionic strength.  This screening results from the asymmetric distribution of small ions as 
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parameterized by the Debye screening length (
-1
 ~  I 
-1/2
) , the distance at which the 
electrical potential due to the protein surface charges decays to 1/e of the protein’s 
surface potential.  This approach, which needs to be clearly differentiated from the 
behavior of condensed counterions,  explains the maximum in binding when 
-1
 ≈ protein 
radius seen for binding at pH > pI for polyanions,
51
 including heparin.
28
  
This approach here is embodied in the DelPhi images of Figure 3.2 for FGF at pH 
7.0 and 400-1000 mM salt. The protein itself is represented at 5Å from Van der Waals 
surface to account for retention of heparin and FGF solvation, and the potential contour 
grids are presented at ψ = 0.2 kT/e. As shown in Figure 3.2 for I = 400 mM, the volume 
between the 5Å surface and the contour grid is sufficient to accommodate at least -5 
heparin charges (1.5-2 disaccharide units, ~2-3 nm dp10 segments), a dimension 
consistent with the FGF-binding site size on heparin.
134
 The consequent electrostatic 
binding energy then is on the order of 1 kT, which represents the onset of the binding. 
50
 
The diminution of this volume seen with increasing salt portrays screening; therefore the 
number of dp10 charges bound is reduced at 550 mM and abolished at 1000 mM as seen 
in Figure 3.1(b). The predominant role of screened electrostatics does not necessarily 
negate release of some bound counterions, but the number of these is debatable.
48
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Figure 3.3: Mass distribution of protein-bound dp10 molecules in FGF·dp10 (blue 
trace) and FGF2.dp10 (green trace) determined at ionic strengths of 250 and 400 
mM. 
 
The stability of the ternary complex requires not only that K4 not compete with 
FGF, but also that the stronger binding of FGF to dp10 does not lead to its occupying all 
potential K4-binding sites. As noted in Figure 3.1, dp10 can bind either one or two FGF 
molecules; the ratio of FGF2·dp10 to FGF·dp10 decreases with salt concentration I, most 
notably near I = 400 mM. This corresponds to a Debye length (κ -1 = 0.4 nm) suggesting 
that screening repulsions at that length scale could weaken the binding.  To further 
explore the difference between the first and second binding events, we consider the 
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sulfation of dp10 molecule found in FGF2·dp10 vs. those found in FGF·dp10. Figure 3.3 
shows, in the absence of K4, the mass spectra of FGF-dp10 complexes plotted on the 
adjusted mass scale where the mass of the protein component was subtracted from 2:1 
and 1:1 complexes at 250 and 400 mM, and represents in blue and green the collection of 
dp10 molecules found respectively in FGF.dp10 and in FGF2·dp10. Given the presence of 
free FGF at all conditions, it might appear if one were to neglect the different sulfation 
patterns that the binding of FGF is anticooperative at high salt. A more reasonable 
explanation can be sought in differences in dp10 sulfation for the first and second binding 
sites, presumably higher for the high-affinity first site. The phase transition-like behavior 
of polyelectrolytes adsorption on oppositely charged surfaces can be extended to binding 
to oppositely charged colloids
135,136
 and oppositely charged proteins.
137
 Critical 
conditions for binding are then expressed by Eq. 3.2:  
b
c
~   Eq.3.2 
where σc is the effective charge density of the protein positive patch, ξ is the 
polyelectrolyte structural linear charge density, b is an empirical scaling parameter and κ 
(nm) ≈ 0.3 I -1/2. According to eq 3.2, the critical ionic strength (above which no binding 
occurs) is described by κc ~ ξ
1/b
. If the high-affinity first binding site is more highly 
sulfated, i.e. ξI> ξII, then κc
I
  > κc
II 
so binding at site I may persist when binding to site II 
is suppressed. Focusing on the results for the 1:1 complexes alone (blue trace in Figure 
3), the increase in dp10 sulfation with ionic strength is consistent with eq 3.2. Typical 
values of b range from 0.5 to 3, a much smaller ionic strength dependence than the I 
-4 
dependence of condensed counterion release, as noted in the comparison of Figures 3.1(a) 
and (b).  
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3.4.3 Ternary complex formation 
 
Figure 3.4: ESI mass spectra of mixtures of FGF (2 μM), dp10 (3 μM), K4 (10 μM) 
in 20 mM pH 6.8 (a) and 100 mM pH 5.5 (b).  FGF present as:  FGF·dp10·K4; 
FGF·dp10; FGF2·dp10; and free FGF. 
  
 
Figures 3.4 (a) and (b) show the ESI mass spectra for a ternary mixture of FGF, 
dp10 and K4 of 2:3:10(µM) stoichiometry at 20 and 100 mM ionic strengths, 
respectively. The signal from dp10.K4 is not shown in Figure 3.4(a) due to excess noise, 
but K4 does appear in the 1:1:1 FGF·dp10·K4 (ternary) complex. The 5:1 excess of K4 
does not impede FGF binding, either because K4 occupies an oligoheparin site distinct 
from that of FGF, or because dp10-K4 binding is intrinsically weaker. The ternary 
complex is less abundant at 100 mM (Figure 3.4(b)) most likely because high salt 
weakens the dp10-K4 interaction (vide supra).  
FGF·dp10 and FGF2·dp10 are observed, the former is more abundant than the 
latter. The restriction of K4 binding to 1 per chain, despite its small size, can be explained 
on the basis of the release of condensed counterions (vide supra), which are more 
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abundant in the middle of dp10. On the contrary, if FGF binding were governed by 
screened electrostatics, the larger effective charge due to less counterion condensation at 
these terminal saccharides could account for facile binding of 2 FGF molecules per chain.  
 
 
 
 
 
 
 
 
 
 
Figure 3.5: The assignment of sulfation levels of dp10 for the FGF·dp10·K4, 
FGF·dp10 and FGF2·dp10 complexes presented in Figure 4 (b). (a) Expansion of the 
m/z regions of FGF·dp10.K4 and FGF·dp10 complexes (nomenclature by Roepstorff 
and Henriksen
138
 for bound dp10). NH4
+ 
adducts on the unbound FGF are shown 
with asterisks (*). The m/z region of FGF·dp10·K4 is amplified 3 times for clarity. b) 
Mass distribution of bound dp10 in FGF·dp10 (blue trace) FGF·dp10·K4 (pink 
trace) and FGF2·dp10 (green trace).  
 
Expansion of the spectral region that comprises FGF·dp10 and ternary complex 
shown in Figure 3.4 reveal the levels of sulfation of the bound dp10 chains (Figure 3.5 (a) 
and (b)).  The sulfation density in the ternary complex, slightly higher than that seen in 
FGF·dp10, suggesting that dp10 chains with low sulfation (< S12) only bind to a single 
FGF, while those with higher sulfation (> S12) can bind K4 along with FGF. The strong 
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suppression of K4 binding at high salt noted above is responsible for the observation of an 
increase in FGF·dp10 at the expense of the FGF·dp10·K4 ternary complex at high salt.  
The extended spectral range at 100 mM salt to include FGF2·dp10 is shown in 
Figure 3.5 (b). Here, the masses of FGF, K4 and 2FGF are subtracted from the calculated 
mass distribution of the complexes in order to compare the sulfation levels of the relevant 
host dp10 chains. Within the limitations of ESI-MS resolution, i.e., the overlapping 
distributions due to the uncertainty in the number of cationizing agents attached to each 
polyanionic chain, the higher mean levels of sulfation (S14 and S15) of dp10 within 
FGF2·dp10 compared to those within FGF·dp10 complexes (S10-14) were observed, and 
chains that contain S12-15 appear to bind both FGF and K4. While chains of low 
sulfation may bind only one FGF, highly sulfated FGF·dp10 chains appear to be subject 
to competition between K4 and FGF for the second binding site. Comparison of the 
highly sulfated (15S) dp10 species in Figure 3.5 (b) suggests that FGF preferentially 
occupies this site. Since K4 binding depends on the condensed layer of counterions, the 
opposing effects of sulfation density and end effects may explain the absence of a clear 
effect of the former. 
Binding to dp10 by K4 and FGF differ in several ways. The salt dependence of 
K4·dp10 complexation is consistent with binding driven by the release of condensed 
counterions; on the other hand, FGF binding to dp10 exhibits higher salt resistance and 
more complex ionic strength dependence consistent with screened electrostatics. While 
FGF2·dp10 complexes are formed over a wide range of ionic strength, dp10 can only bind 
one K4. Estimates of the size of the FGF-binding site on heparin suggest ca. two 
disaccharides, similar to the mean protein hydrodynamic radius i.e. 2 nm, consistent with 
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the maximum number of proteins that can bind to native Hp.
134
 K4 (≈ 2 nm contour 
length) can then be easily accommodated near the center of dp10 with a distal region of 
higher effective charge density accessible for FGF.  FGF binding is facilitated by high 
dp10 sulfation, whereas the effect of sulfation levels on K4 binding can be obscured by 
the conjoint influence of end effects on the concentration of dp10 condensed counterions. 
These observations pointed out that control of I and overall sulfation levels of 
heprarinoids could be used to manipulate the balance between matrix component- and 
growth factor affinity in tissue engineering. The selection of the conditions could be used 
to influence the rates of morphogen release and also the presence or absence of heparin 
accompanying the free growth factor.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Models of FGF release 
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The stability of the FGF·dp10 versus K4·dp10 complexes at selected conditions 
will determine which bond will break first in the tissue scaffolds to release FGF, and as a 
result of this breakage, FGF will be released with or without heparinoid. The use of low 
ionic strength (< 40mM) during the assembly process should enhance ternary complex 
formation and higher ionic strength of the environment could lead to the dissociation of 
the dp10- K4 bond first; then GF would be released in the heparinoid-bound form during 
the dissociation process (Figure 3.6). In addition to addition of salt, increasing the 
degrees of sulfation definitely promotes capturing a large number of growth factors and 
the formation of ternary complexes. Therefore, heparin chains with higher degrees of 
sulfation could be used to deliver high concentration of GFs in the tissue environments.  
3.4.4 Biological activity of FGF vs FGF·dp10·K4 
We investigated whether the complexation of FGF to dp10 and K4 would alter its 
bioactivity when compared to FGF alone (Figure 3.7). HEP3Bs were stimulated with 
FGF or FGF complex across concentrations ranging from 0 to 50 ng/mL. We found that 
binding of dp10 and K4 to FGF does not significantly alter its activity at any of the tested 
concentrations. As expected, HEP3B proliferation at 24h increased by approximately 
10% with FGF and FGF complex as compared with the control. After 72 h, cell 
proliferation is maximized, and neither treatment showed any significant difference in 
proliferation across the concentrations tested here.  
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Figure 3.7: FGF·dp10·K4 mixture retains biological activity of FGF·HEP3Bs were 
treated with either FGF (black) or FGF·dp10·K4 (red), and cell proliferation was 
quantified at 24 (solid) and 72 hours (dashed). No statistical differences were noted 
when comparing cell proliferation with FGF and the FGF·dp10·K4, at any time 
point.  Proliferation increases with FGF concentration at 24 hours, and is 
maximized at all concentrations at 72 hours. In both formats, FGF of 50 ng/mL is 
statistically higher than the no growth factor condition at 24 hours. 
3.5 Conclusions 
A heparin decamer (dp10) in the presence of tetralysine (K4) can bind either one 
or two molecules of acidic fibroblast growth factor (FGF), or FGF and K4, but cannot 
bind two molecules of K4. Using electrospray mass spectrometry (ESI-MS) to investigate 
the ionic strength effect on the formation of these complexes, we concluded that the 
formation of K4-dp10 is driven by the release of condensed counterions. We have 
previously shown that the concentration of condensed counterions on dp10 is strongly 
reduced near its chain termini, and therefore propose that K4 binding is constrained to the 
central region of dp10. The markedly different ionic strength dependence of FGF binding 
suggests a different mechanism (based on screened electrostatics), which removes this 
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constraint, so that the growth factor can bind along with K4 (“ternary complex”) or along 
with a second FGF.  ESI-MS characterization of bound dp10 chains in various complexes 
indicates that FGF binding is enhanced by heparin sulfation, while K4 binding is 
relatively indifferent to it due to competing effects. Cell culture studies indicated that 
complexation of FGF in the form FGF-dp10-K4 does not significantly change its 
biological activity. These observations suggest the application of shorter heparin chains 
as a route to growth factor sequestration and release in tissues matrices could be more 
effective than the use of heterogeneous native heparin chains.  
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CHAPTER 4 
STRUCTURAL DETERMINANTS OF ELECTROSTATIC INTERACTIONS 
BETWEEN PROTEINS AND POLYANIONS: AN ESI-MS STUDY OF 
FIBROBLAST GROWTH FACTOR BINDING TO HEPARIN OLIGOMERS 
 
Minsky, B. B.; Dubin, P. L.; Kaltashov, I. A. 
4.1 Abstract 
The interactions between fibroblast growth factors (FGFs) and their receptors 
(FGFRs) are facilitated by heparan sulfate (HS) and heparin (Hp). The molecular basis of 
this modulation is highly complex due to the structural heterogeneity of HS/Hp, with 
regard to both chain length and sulfation. In this work, we employed electrospray 
ionization mass spectrometry (ESI-MS) to investigate the association of acidic fibroblast 
growth factor (FGF-1) with relatively homogeneous heparins octamer (dp8) and decamer 
(dp10). FGF-1 forms 1:1, 2:1 and 3:1 (FGF:heparinoid) complexes with dp8/dp10, and 
the fraction of bound protein is highly dependent on FGF:heparinoid bulk stoichiometry. 
The multimeric complexes were preferentially formed on the highly sulfated Hp 
oligomers. When solution stoichiometry led to only 1:1 complex, the sulfate distribution 
of FGF-bound oligomers was skewed from low to high in the complex. These results 
showed how interactions between FGF-1 and Hp oligomers are influenced by the heparin 
oligomer charge density and bulk mixing ratio, and also demonstrate the power of ESI-
MS as a tool to study multiple binding equilibria between proteins and highly complex 
polyanions.   
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4.2 Introduction 
Glyscosaminoglycans (GAGs), such as heparan sulfate (HS) and heparin (Hp), are 
engaged in a wide spectrum of physiological effects including embryogenesis, immune 
response, cell proliferation, differentiation and angiogenesis. All of these are related to 
the ability of GAGs to potentiate the activity of numerous signaling proteins, 
accomplished largely by mediating the interactions of these growth factors and their cell 
surface receptors. The main challenge in characterizing GAG-protein binding arises from 
the immensely polydisperse GAG structure due to apparently stochastic post-translational 
sulfation patterns. While this polydispersity correlates with promiscuity in protein 
binding, the details of the relationship between the sulfation and protein affinity remain 
elusive. The fact that GAGs are the most highly charged macromolecules in animals 
suggests that electrostatic forces play significant roles in their protein affinity, but such 
long-range interactions are typically relegated to supportive roles in protein recognition. 
The development of structure-property relations, which would remove a major barrier to 
the development of potential biomedical applications of GAG’s, is thus coupled to the 
need to understand how sulfation patterns determine binding of their physiological 
partners. While many approaches focus on the presence or absence of a particular 
glycoside or glycoside substituent, electrospray ionization mass spectrometry (ESI-MS), 
focusing on the characterization of individual molecules, can provide unique insights into 
the structural distinctions between high and low affinity GAG molecules.  
Efforts to characterize HS/Hp interactions with growth factors (GF) have until 
recently focused on the contribution of certain sulfation features, such as 6-O- sulfation 
for FGF-10, 2-O sulfation for FGF-2, or both for FGF-4 and FGF-7.
117,118
 The underlying 
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assumption is that the protein-heparinoid interaction is driven by pair-matching of basic 
residues on the protein and sulfates on heparin, the fact that heparin was clearly and 
credibly identified 30 years ago as a polyelectrolyte
11
 notwithstanding. In most studies, 
the importance of more global “charge complementarities” between the protein and the 
polyelectrolyte-like heparinoid had been ignored,
17,44
 thus failing to consider the 
heterogeneity and highly dynamic nature of the Hp/HS chains,
10
 and the well-defined 
positive domains of the many globally negative heparin-binding proteins.
139
 There is 
increasing evidence that strong binding occurs between globally negative proteins (such 
as antithrombin) and polyanions (such as heparin) when polyanion charge distributions 
are arranged in a way that minimizes long-range repulsion while optimizing short range 
attractions with locally positive protein domains. This can result in a level of selectivity 
that does not arise from short-range interactions such as hydrogen-bonding or “ion-pair” 
formation.
31,51,121
 Supporting this perspective, several groups suggested that GAG-GF 
interactions might be intrinsically non-specific. Catlow et al. showed that the interaction 
of hepatocyte growth factor/scatter factor with HS is dominated by electrostatics.
34
 
Krueger et al. indicated that various FGFs share the same binding domain on HS, where 
binding affinity is correlated with the extent of sulfation.
21
 Jastrebova et al. extended 
these studies to FGF-2 and its receptors, and revealed that ternary complex formation was 
related to overall chain sulfation.
20,35
 These studies strongly suggest that non-specific 
electrostatic interactions can play a role in recognition.
45
 
For various signaling proteins, certain sequences in GAG structure may either 
interact with protein multimers or promote multimerization.
38
 In this way, FGF-HS 
binding in the distal region of cell surfaces generates FGF dimers along HS 
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chains.
134,140,141
 Evidence, both in vivo and vitro, suggests that these dimers are the 
biologically preferred architecture for inducing receptor activation.
142
 The crystal 
structure of FGF-2 with a heparin decamer (dp10) revealed the existence of a homodimer, 
or “cis-dimer"143, in contrast to the “trans-dimer” formed for FGF-1 with a 4-5 
monosaccharide sequence sandwiched between the two proteins.
144
 Other oligoheparins 
larger than heptasaccharides can lead to biologically active FGF-1 dimers
145
. In vitro light 
scattering studies of full-length Hp have shown that it accommodate 14-15 FGF-1 
molecules.
134
   
Sulfation sequence arrangements are clearly determinants of the intra-
polysaccharide organization of bound proteins, but the techniques mentioned above only 
reflect the average behavior of intrinsically heterogeneous heparin oligomers. On the 
other hand, the unmatched resolution of mass spectrometry provides insight into the 
behavior of single molecules, clearly correlating sulfation level and protein-oligoheparin 
stoichiometry.  Native electrospray ionization mass spectrometry (ESI-MS) is thus an 
important tool in the detection of non-covalent protein-ligand complexes,
146
 revealing 
compositional details of macromolecular complexes that involve nucleic acid and 
heaprin.
88,127,128
 Increased sensitivity, low sample requirements and ability to detect 
dynamic and transient complexes have contributed to the importance in this field. 
Therefore, we applied native ESI-MS to probe interactions of FGF-1 and short 
heparinoids, focusing on the influences of heparin chain length, extent of sulfation and 
solution concentration on the induction of multimeric complexes of FGF-1. Analysis of 
the number of sulfate groups on the Hp chains involved in complex formation revealed 
the basis of FGF-1 selectivity of Hp chains. 
64 
 
4.3 Experimental 
4.3.1 Materials  
Acidic fibroblast growth factor (includes His to Gly 93 mutation to increase 
stability,
129
  pI = 7.8) was provided by Prof. Robert Linhardt (RPI, Troy, NY).  Octa and 
decasaccharides (dp8 and dp10), prepared by partial heparin lysis, followed by high-
resolution gel filtration, were generously donated by Dr. John Gallagher from Iduron 
(Manchester, UK).  
4.3.2 Methods 
4.3.2.1 Electrospray Ionization Mass Spectrometry (ESI-MS) 
All experiments were performed with a QStar-XL hybrid quadrupole-time-of-flight MS 
with a nano-ESI-source (AB Sciex, Toronto, Canada). The measurements were 
performed using both closed and pre-opened (1-2 μm id) glass nanospray capillaries 
(New Objective, Woburn, MA). ESI-MS was used to determine stoichiometries of FGF-
1-dp8/dp10 complexes and monitor depletion of dp8/dp10. Growth Factor concentration 
was kept constant during each experiment (0.08 g/L, ca. 5 μM) and dp8/dp10 
concentration was adjusted to 1, 2.5, 5, 10 and 25 μM at 100 mM NH4CH3CO2 at pH 6.8. 
FGF-1 was buffer exchanged using Amicon (10 kDa cut off) with 100 mM NH4CH3CO2, 
and the concentration was verified by UV-VIS using molar absorptivity of 17545 M
-1
cm
-
1
. Dp8 and dp10 were diluted from 2 mg/mL stock solutions. Binding experiments were 
acquired using following settings of ion optics in the ESI interface:  DP, 100; FP, 265; 
DP2, 15 and dp8/dp10 depletion experiments are acquired under mild ionization 
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conditions (DP, 40; FP, 150; DP2, 15),where DP is the declustering potential and FP is  
focusing potential. The mass distribution of the protein-bound heparinoid molecules were 
calculated using the Eq. 4.1. 
FGF
nMmHz
z
m
  Eq.4.1 
where n represents total number bound FGF-1 molecules, m is the total protons attached 
and MFGF is the mass of a single FGF molecule.  
4.3.2.2 DelPhi Calculations  
DelPhi V. 4r1.1,
130,131
 which applies non-linear Poisson-Boltzmann equation to 
generate the potential surface of the protein, was used to model the electrostatic potential 
around FGF-1 (PDB id: 1K5U) at the experimental conditions as described (pH 7.0, I = 
100 mM). The structures were taken from the protein data bank (http://www.rcsb.org/). 
The charges of amino acids on the protein were determined using Tanford’s spherical-
smeared charged model.
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4.3.2.3 Monte-Carlo Simulations 
The MC technique with the Metropolis algorithm
147
 was used for generating 
equilibrium states. The MC technique ensures that the system eventually reaches thermal 
equilibrium for the oligomer-protein complex. Heparin was presented by a decamer of 6 
units of acrylamidopropylsulfonate and 4 units of acylamide; this AMPS-AAm oligomer 
has the same chain length and net charge as the well-known heparin pentasaccharide.
19
 
The temperature chosen for the simulations was T = 300 K. The charges on the various 
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residues were those appropriate to FGF-1 at pH 7.0 and protein was modeled as partially 
coarse-grained.  
4.4 Results and Discussion  
4.4.1 Heparin facilitates formation of FGF-1 multimeric complexes 
The ESI mass spectrum of FGF-1 (5 M) in the absence of heparin oligomers 
showed no evidence of dimers or higher-order multimers (Figure 4.1). However, in the 
presence of dp8 or dp10, at concentrations ranging from 1.25 to 25 M corresponding to 
[FGF] / [Hp] ratio r = 4, 2, 1 and 0.2,  formation of 1:1, 2:1 and 3:1 (FGF:heparin) 
complexes were observed (Figure 4.1a and 4.1b). When FGF was in excess relative to 
heparin, 3:1, 2:1 and 1:1 complexes were detected, but the 3:1 complex formation was 
most prominent in the presence of dp10  (Figure 4.1b). On the contrary, the 1:1 complex 
was detected as the most populated ionic species in the case of the excess heparinoid (at r 
= 0.2). 
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Figure 4.1: ESI mass spectra of FGF-1/heparinoid complexes at 100 mM 
NH4CH3CO2, pH 6.8 (a) r ([FGF-1] / [dp8]) = 2, 1, 0.2 and 0. (b)  r ([FGF] / [dp10]) = 
4, 1, 0.2 and 0. The charge state distributions of free protein, 1:1, 2:1 and 3:1 
complexes are presented gray, blue, pink and green labels, respectively. 
 
The dependence of complex stoichiometry on the mixing ratio suggests a multiple 
binding equilibrium with heparin as the host molecule. For excess heparin, the presence 
of free protein indicates either that affinity is low, or that high affinity sites are fully 
occupied. These results, however, do not reveal how such high and low affinity sites are 
distributed among the heparin chains. 
The formation of 3:1 complex, particularly favorable at high r (excess protein), 
brings up the need to explain how the heparin oligomer chain can accommodate three 
FGF molecules. The DelPhi image of FGF-1 (Figure 4.2), showing the 0.5kT/e 
electrostatic potential contours, indicates a dominant positive patch at pH 7.0, I = 100 
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mM. Even though the exact location of the bound Hp chain cannot be determined, it can 
be assumed that highly negative heparin would avoid the negative domains of the protein. 
Such predominant electrostatic effects make the classical “lock and key” interaction 
unlikely. The immediate vicinity of the positive domain can be viewed as creating a 
strong attraction basin for polyanions without forcing them into highly defined and thus 
entropically disfavored conformations. This dynamic behavior notwithstanding, the FGF-
binding site size on heparin of 4 contiguous units (~2 nm) as determined from dynamic 
and static light scattering studies,
134
 would seem to indicate that dp10 (contour length 5 
nm) could not realistically bind three FGF-1’s with hydrodynamic diameters of 4 nm, 
particularly in a cis complex.  However, heparin, a semi-flexible chain,
10
  can exhibit 
local conformations in solution
148
 to facilitate FGF-1 binding from multiple directions , 
i.e., formation of a trans complex (as in Figure 4.2b and c).  
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Figure 4.2: (a) Electrostatic potential contours (-0.5 kT/e (red) and 0.5 kT/e (blue)) 
generated around FGF-1 (PDB id: 1K5U) at 100 mM pH 7.0. Possible models for the 
structural arrangements of the (b) 2:1 and (c) 3:1 complexes are presented.  
 
 
Additional evidence for the arrangements of the 3:1 complexes can be deduced 
from Monte Carlo simulations of the FGF-bound Hp-mimetic oligomer chain. Simulation 
snapshots shown in Figure 4.3, indicate that only a small part of the polyanion interacts 
with the protein at any instant. From this point of view, three FGF may be “bridged” by 
dp10, in the sense that they are highly co-localized with transient interactions with the 
oligoheparin overcoming intrinsic inter-protein repulsions. 
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Figure 4.3: The MC snapshots of FGF and charged decamer residing at the FGF 
binding site at pH 7.0 and I =10 mM. FGF is represented with the electrostatic 
potentials at 0.5 kT/e, red and blue correspond to negative and positive protein 
potentials via solutions of the nonlinear Poisson-Boltzmann equation. The frames 
shown (a) through (f) are 25K MC steps apart and they are in the range of 225K to 
350K MC steps (Courtesy of Daniel Seeman).   
 
4.4.2 Higher sulfated chains promote formation of multimeric complexes of FGF-1   
Heparin structure is immensely heterogeneous due to the seemingly random 
placement of sulfate groups (Figure 4.4). Dp8 and dp10 fragments exhibit structural 
polydispersity with respect to both total levels of sulfation and their distribution across 
the polysaccharide backbone.  
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Figure 4.4: Repeating disaccharide unit of heparin oligomers. The possible locations 
for sulfate substitutions are shown in red. ( n is equal to 4 and 5 for dp8 and dp10, 
respectively.)  
 
Observation of different stoichiometric complexes with dp8 and dp10 indicated 
existence of multiple biding sites with various levels of affinity for FGF-1. In order to 
identify the structural features, i.e. degrees of sulfation of the dp8 and dp10 binders, the 
mass distribution of bound dp8/dp10 was determined. Mass to charge ratio for the most 
abundant peak of a protein/heparinoid complex (+7 for 1:1, +12 for 2:1 and +14 for 3:1) 
was converted to neutral mass using Eq. 4.1, and the mass distribution of the bound dp8 
and dp10 are presented in Figure 4.5 and 4.6. Since all analyses were performed in the 
positive ion mode, each ionic species also contain 4-5 cations (NH4
+
). Therefore, shaded 
boxes are used in Figure 4 and 5 to indicate the mass ranges for heparinoid species with 
different extent of sulfation (the overlap is due to the uncertainty in the number of 
cationizing agents attached to each polyanionic chain). We used Roepstorff-Henriksen 
nomenclature (X,Y,Z)
80
 to present sequence distribution of dp8/10, in which X represents 
number of saccharide, Y is the number of  sulfate  and Z is the number of acetyl groups. 
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Figure 4.5: The mass distribution of the bound a) dp8 in the r = 0.2 and 1, b) dp10 in 
the r = 0.2, 1 and 4 are shown. Blue trace represents the +7 charge states of the 1:1 
complexes, pink trace is the +12 charge states of the 2:1 complexes and green trace 
is the +14 charge states of the 3:1 complexes. 
 
In Figure 4.5 (a), mass distribution of protein bound-dp8 molecules in 1:1 (blue 
traces) and 2:1 (pink traces) complexes were plotted for r = 1 and r = 0.2. A comparison 
of these two profiles indicates that protein bound dp8 chains carry 8 to 12 SO3
-
 groups.   
In both cases, the 2:1 complexes were formed only on the highly sulfated chains (11 and 
12 SO3
- 
groups per chain). Low sulfated chains (with 8, 9 and 10 SO3
-
), retained the 
binding affinity for FGF-1, but they facilitated formation of only the 1:1 complex. 
Increasing dp8 concentration (r = 0.2) shifted the complex equilibrium towards 1:1 and 
the degree of sulfation in the 1:1 complex skewed towards higher sulfation, possibly 
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reflecting the fact that the lower charge density heparinoids are capable of binding to 
FGF-1 when their higher charge density counterparts became completely consumed. 
Figure 4.5 (b) represents the mass distribution of protein-bound dp10 chains in 
1:1 (blue traces) and 2:1(pink traces) complexes at r = 0.2, r = 1 and r = 4.  In addition to 
1:1 and 2:1 complexes, 3:1 complexes (green trace) are also observed at r = 4, and 3:1 
complexes are formed on the chains containing 14 and 15 SO3
-
 groups. The 2:1 
complexes are formed in the intermediate range of sulfation (11 to 13 SO3
-
) and finally 
the 1:1 complex contains low sulfated chains. Higher dp10 concentration (r = 1) raises 
the number of available binding sites for FGF-1, as a result the ionic signal for the 3:1 
complex is quite low, and the degree of sulfation in 2:1 and 1:1 complexes is skewed 
towards higher sulfation, 12-15 and 10-14 SO3
-
 groups, respectively. When dp10 
concentration is in 5-fold excess over FGF-1 (r = 0.2), only the 1:1 complex formed, in 
which low sulfated chains are replaced by the high sulfated dp10 chains (the number of 
sulfation is varied from 11 to 15).  These results could indicate that: (1) highly sulfated 
chains are occupied first; (2) high sulfated chains have multiple binding sites (up to 3) 
with various degrees of affinity for FGF-1; (3) low sulfated chains are capable of binding 
to FGF-1; however the affinity is lower than highly sulfated ones.   
4.4.3 When bulk stoichiometry leads to a significant amount of bound heparin, the 
charge density of the free heparin is low relative to the initial heparin 
In this work, we utilized mass spectrometric approach to evaluate importance of 
heparin sulfation for FGF1-dp10 binding. While binding preferences of proteins towards 
Hp have been generally determined by analyzing protein/Hp complexes,
149,150
 an 
alternative approach to this question utilized monitoring differential depletion of small 
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molecule ligand from the entire ensemble of heparinoid molecules upon addition of 
binding partner.
88
 Figure 4.6 (a) and 4.6 (b) demonstrates bound and unbound dp10 mass 
distribution for r = 1, r = 0.5 and r = 0.2, respectively. The calculation described for 
Figure 4.5 was applied to obtain mass distribution of protein-bound dp10 species (Figure 
4.6 (a)). Unbound (free) dp10 species appears at 1200 < m/z <1600 at +2 charge states 
and m/z values were transformed to the mass distribution.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: The mass distribution of the a) bound and b) unbound dp10 species at r 
= 1, 0.5 and 0.2  
 
Mass distribution of unbound dp10 extends beyond that of the protein-bound 
dp10, because dp10 contains 11- 14 NH4
+
 adducts when they are free in solution, as 
opposed to 4-5 NH4
+
 in the protein-bound form. The depletion of dp10 species was more 
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pronounced at r =1, where the 2:1 ionic signal was more abundant and highly sulfated 
chains (14 and 15 SO3
-
groups) facilitated the complex formation. Moderate to low 
number of sulfated groups were engaged in the formation of 1:1 complex (10 to 13 SO3
-
), 
in which the majority of the binders carry 12 and 13 SO3
-
 groups. This observation is 
clearly consistent with the Figure 4.6 (b): dp10 chains incorporating 13-15 sulfate groups 
are almost completely depleted; therefore ionic signal from 10 to 12 sulfated species 
becomes more abundant on a relative scale.  The r = 0.5 presents a transition stage in that 
the 2:1 complex ionic abundance decreased and sulfation distribution is skewed to higher 
sulfation for the 1:1 complex. Similarly, depletion of the highly sulfated species is quite 
evident at r = 0.5, as seen in Figure 4.6(b). Since dp10 concentration was quite high 
relative to the protein at r =0.2, the depletion of the dp10 chains was minimal, and 
protein-free dp10 spectra (r = 0) and r = 0.2 free regions are almost identical. 
These results support the previous identification of highly sulfated species as 
primary agents triggering formation of in the FGF-1 multimers. The heparin chains may 
exhibit not only intra-chain heterogeneity, but also inter-chain diversity so that the chains 
having same number of sulfates may not have the same distribution of sulfate groups. 
The arrangement of the sulfate groups within these chains can occur in numerous ways 
considering the possible locations in a disaccharide as represented in Figure 4.4. There 
are 20 sites available for sulfation within dp10, and if these sites are assumed to have 
equal probability of carrying a sulfate group; the possible ways to distribute sulfate 
groups can be calculated by:  
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where n  is the total sites  and k is the number of sulfate groups.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: The number of possible structural arrangements depending on the 
number of sulfate groups within dp10. 
 
The results obtained by using Eq. 4.2 are presented in Figure 4.7.  The number of 
variations to distribute sulfate groups is lower in the highly sulfated chains; therefore, the 
possibility of having equally distributed charges, i.e. “charge segments”, along the chain 
is higher.  As seen in Figure 4.6 (b), highly sulfated dp10 chains (carrying 14 and 15 
sulfate groups) were completely depleted at r = 1, on the contrary dp10 chains carrying 
10- 12 sulfate
 
groups are more abundant on a relative scale. Structural variations are 
higher for these chains; therefore the probability of having a “charge segment” is much 
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lower. These observations could explain (1) the preferential binding between FGF-1 
molecules and the highly sulfated chains, in which highly sulfated chains can provide 
properly arranged charged domains for FGF-1; (2) the incapability of the low sulfate 
chains to induce multimeric complexes of FGF-1 due to the decreased amount of “charge 
segments”.  
4.5 Conclusions  
ESI-MS results suggested that the nature of the FGF- heparinoid interaction was 
“promiscuous” in that both high and low sulfated chains could be involved in binding 
events. Highly sulfated dp8 and dp10 chains are involved in multimer formation than 
lower sulfated chains. When dp8/dp10 is excess, low sulfated binders are replaced with 
highly sulfated ones in the 1:1 complex, which is a clear representation of the 
competition between low and high sulfation in protein recognition. The formation of 3:1 
complexes on highly sulfated dp10 chains also indicates a packed structure, in which 
proteins could be bound with close proximity. Heparin induced multimerization of FGF 
on the varying degree of sulfation could be an evidence that heparin oligomers 
“concentrate” FGF molecules along the heparin chain; therefore the probability of the 
receptor interaction could be increased. Furthermore, these studies emphasize the power 
of ESI-MS to characterize protein interactions with the highly heterogeneous targets.  
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CHAPTER 5 
ELECTROSPRAY IONIZATION MASS SPECTROMETRY STUDY TO 
REVEAL THE EFFECT OF HEPARIN CHAIN LENGTH ON ANTITHROMBIN 
AND FACTOR XA COMPLEX FORMATION 
Minsky, B. B.; Abzalimov, R; Dubin, P. L.; Kaltashov, I. A. 
5.1 Introduction 
Full-length heparin, low molecular weight heparins and small molecule heparin 
analogs have been administered as anticoagulant drugs for decades; however, their 
efficacies are reduced by the high risk of bleeding
151
 and the requirements of patient-
dependent dose administrations.
152
 Safer and more effective therapies can be achieved 
through greater understanding of the way that heparin mediates antithrombin and 
protease binding, which is a central inhibitory process in coagulation. However, the 
accuracy of models for the binding of  antithrombin and coagulation proteases  is a matter 
of controversy. In this study, we monitor complexation of antithrombin (AT) and 
coagulation protease Factor Xa (FXa) in the presence of defined-length heparin (Hp) 
oligomers using electrospray ionization mass spectrometry (ESI MS) in order to compare 
the capabilities of various length heparin oligomers to induce binary (AT·FXa) and 
ternary (AT·FXa·Hp) complexes.  
Antithrombin, a natural anticoagulant in the blood, inhibits coagulation proteases, 
predominantly thrombin and Factor Xa, by forming equimolar and stable complexes.
153-
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155
 Although this process occurs naturally in the blood, the binding process is extremely 
slow. Heparin and heparan sulfate enhance the rate of antithrombin-thrombin/Factor Xa 
complex formation by up to several orders of magnitude.
156
 In both cases, heparin acts as 
a catalyst, and therefore it is not necessarily a part of the final complex.
33
 The mechanism 
of AT-protease binding has been suggested to follow two sequential events: (1) diffusion-
controlled formation of an encounter complex; (2) formation of a reaction-controlled 
stable covalent complex.
33,157
 If heparin promotes the encounter complex, its role would 
be basically confining two proteins on the same chain, so they have more time to interact. 
This "approximation effect" is suggested for AT-thrombin binding.
158
 If heparin 
modulates the reaction part, it would do so by inducing  the conformational change on 
AT: this mechanism is proposed for AT-FXa interaction (allosteric effect).
159
  
The minimal heparin length required to promote the approximation effect is 18 
monosaccharide units;
158
 whereas a specific pentasaccharide has been proposed to be 
capable of activating AT towards Factor Xa
160
  as a result of an induced conformational 
changes on AT (allosteric activation). This model has been challenged by recent studies 
showing that binding to heparin chains of various length does not significantly change 
secondary structure, but in fact enhances the conformational stability of AT, a stronger 
effect observed  with shorter heparin oligomers.
161
 The formation of encounter complexes 
and an approximation effect have also been experimentally observed for AT-FXa in the 
presence of longer chain heparins.
162
 Calcium ions have been shown to improve anti-FXa 
activity with increasing Hp chain length.
163
 Consistent with the approximation effect 
model recent findings indicate that long chain heparins enhance AT-FXa binding, even in 
the absence of calcium ions.
164
 In the crystal structure of Factor IXa, a crystal contact was 
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observed with heparin pentasaccharide, which was interpreted as a possibility for longer 
chain to form encounter complex.
165
  
The anticoagulant activity of heparin was famously ascribed to a unique pentamer 
carrying a rare 3-O-sulfate substitution,
18
 but many observations run counter to this yet 
influential paradigm. Recent studies indicate that 3-O-sulfate substitution may not be 
needed to promote allosteric activation of AT.
166
 Less complex polyanions, such as, 
sulfated dextran
167
 and sulfated lignins,
168
 can imitate Hp function in AT-FXa binding. 
The putative interaction between AT and the high-affinity binding specific 
pentasaccharide embodied directionally specific short-range interactions (H-bonds and 
salt bridges).
17-19
 This concept of specificity essentially incorporates a frozen state of AT-
bound heparin despite the intrinsic flexibility of oligoheparins.
9
 Furthermore, non-
monotonic salt dependence, difficult to rationalize on the basis of short-range attraction 
alone, has been observed for AT and low molecular weight and full-length heparin 
interactions,
28
 as for other protein-polyelectrolyte systems.
51
 These observations highlight 
the significance of the combinations of short-range attractions and long-range repulsions 
between the negatively charged heparin and the highly anisotropic protein surface 
charges,
28,44,51
  and introduce a nuanced view of specificity that takes into account the 
charge complementarity between the protein surface and the polyanion.
31
  
The stoichiometry and the mechanistic interpretations of AT-FXa binding have 
primarily evolved from crystallography studies,
23,169
 involving short heparin analogs. In 
this way, the effects of the intrinsic heterogeneity of biologically relevant heparin chains 
could be overlooked. Therefore, in order to investigate the AT-FXa complex 
stoichiometries, we use a set of well-defined heparin oligomers, whose chain lengths 
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range from hexa- to icosasaccharide.  Electrospray ionization mass spectrometry (ESI 
MS) serves this purpose exceptionally well by providing remarkable structural details and 
revealing complex stoichiometries. 
 
5.2 Experimental  
 
Human α-AT (MW = 57.8 kDa), was purified from human plasma using heparin 
affinity chromatography, generously donated by CSL Behring (Marburg, Germany),. 
Heparin oligomers (dp6, dp8, dp10 and dp20) and native heparin were provided by John 
T. Gallagher (Iduron, Manchester, UK). Human Factor Xa, which is a mixture of α (45.3 
kDa) and β (43.3 kDa) subforms, was purchased from Haematologic Technologies, Inc 
(Vermont, USA). Factor Xa(β) is formed as a result of autoproteolysis of  Factor Xa(α), 
and both subforms have equal roles in coagulation.
170
 Protein and heparin oligomer 
solutions for ESI MS analysis were prepared in 150 mM ammonium acetate at pH 7.0 to 
final concentrations of 1.8 μM for AT and 1.8 μM for FXa, and 7.5 to 15 μM for heparin 
oligomers. All binding experiments, both in the absence and in the presence of heparin 
oligomers, were completed within an hour after mixing of the components.  ESI MS 
experiments were performed with a QStar-XL hybrid quadrupole-time-of-flight MS with 
a nano-ESI-source (AB Sciex, Toronto, Canada) and the measurements were performed 
using closed (2 μm id) glass nanospray capillaries (New Objective, Woburn, MA).  
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5.3 Results  
5.3.1 Short heparin oligomers induced formation of AT·FXa binary complex  
 
Figure 5.1A shows the ESI mass spectra of AT-FXa in the presence of dp10 with 
concentrations varying from 0 to 15 μM. In the absence of dp10, the ionic signal 
representing AT·FXa complexes is in very low abundance, whereas free AT and free FXa 
species contribute to the ionic signal significantly.   
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Figure 5.1: ESI mass spectra of AT (1.8 μM) and FXa (1.5 μM) in the absence and 
presence of Hp oligomers at 150 mM ammonium acetate, pH 7.0. A) The 
dependence of  AT and FXa  binary complex formation to dp10 concentration. B) 
AT and FXa complex formation with various lengths heparin oligomers ( dp6, dp8 
and dp10) using 15 μM of oligomers. The notations represent: Bα = AT + FXa (α ) = 
103.3 kDa and Bβ = AT + FXa (β ) = 101.3 kDa 
 
In the presence of dp10, ESI MS spectra provide clear evidence for the formation 
of 1:1 AT·FXa complexes.  Raising dp10 concentration from 0 to 15 μM leads to a 
progressive increase in AT·FXa complexes and a decrease in free FXa ionic species. In 
the presence of dp10, the resultant complex was assigned to a mass distribution with a 1:1 
AT·FXa stoichiometry and dp10 was not detected as a part of the complex, at least with 
the standard deconvolution methods. Using 15 μM dp10 concentration results in optimal 
ratio of AT·FXa to free AT and FXa ratio; thus this concentration was used to determine 
complex stoichiometries with even shorter heparin oligomer chains. As seen in Figure 
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1B, similar binding patterns were observed between AT an FXa in the presence of 15 μM 
dp6, dp8 and dp10, and there was no evidence for the ternary AT·FXa·dp6 and 
AT·FXa·dp8 complexes. 
In order to provide further evidence for the absence of ternary complexes,  dp10 
free and dp10 present spectra are overlaid in the AT·FXa complex region (4600 < m/z < 
5200), and  peak widening was observed in the dp10 present spectrum (Figure 5.2A). The 
wider peaks could be an indication of the presence of AT·FXa·dp10 complexes; therefore 
these peaks were deconvoluted using Gaussian fittings to investigate any possible 
contributions from AT·FXa(α)·dp10 and AT·FXa(β)·dp10 complexes. The widths of 
these complexes were estimated relative to the AT·dp10 complex, which is already 
present in the spectra. As seen from the Figure 5.2B, there is a small contribution from 
AT·FXa·dp10 complexes, and this contribution does not exceed 20% of the total binary 
complex.  
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Figure 5.2: A) Superimposition of AT-FXa and AT-FXa-dp10 spectra in the binary 
complex region. B) Gaussian fittings to investigate the contributions of ternary AT-
FXa-dp10 complexes to the binary complex 
 
5.3.2 Longer chains induce formation of higher order AT-FXa complexes (dp20 and 
native heparin chains 
 
Short heparin chains (dp ≤ 10) facilitated AT-FXa interaction, and intriguingly 
these chains were dissociated from the resultant complex in the course of the 
experimental time scale. However, longer heparin chains (dp 20) were capable of 
inducing AT·FXa(α)·dp20 and AT·FXa(β)·dp20 complexes, corresponding to 107.3 kDa 
and 109.3 kDa complexes, respectively (Figure 5.3A). Gaussian fittings were generated 
using the peak shapes of the AT·dp20 complex and the resultant peaks matched with the 
AT·FXa(α)·dp20 and AT·FXa(β)·dp20 complex peaks. This analysis distinctly 
demonstrates that AT·FXa complexes are absent from the spectra (Figure 5.3B).  
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Figure 5.3: A) ESI mass spectra of AT (1.8 μM) and FXa (1.5 μM) in the presence of 
heparin dp20 (7.5 μM) at 150 mM ammonium acetate, pH 7.0 representing ternary 
AT-FXa(α )-dp20 ( 109.3 kDa) and AT -FXa (β )-dp20 (107.3 kDa ) complexes. B) 
Gaussian fittings to validate ternary AT-FXa(α )-dp20 and  AT -FXa (β )-dp20 
complexes. 
 
The concentration of dp 20 used in this experiment was 7.5 μM, and this amount 
was sufficient to induce the formation of AT·FXa·dp20 complexes and deplete the free 
FXa components notably. Similar complex formation and depletion patterns were 
obtained using a 15 μM concentration of shorter heparin oligomers (dp ≤ 10). In addition, 
the relative abundance of free AT as a function of heparin oligomer chain length is 
significantly lower with dp20 compared to the shorter heparinoids (dp ≤ 10).  
AT and FXa binding, in the presence of native (un-fractionated) heparin 
represents the most challenging case. Figure 5.4 shows the addition of ~2.4 μM native 
heparin at the same conditions used for shorter heparinoids in AT and FXa binding 
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experiments. Even though the relative abundances of free AT and FXa components have 
been substantially decreased, the immense structural heterogeneity of native heparin 
limits any meaningful interpretations for the probable AT-FXa complexes in the m/z 
region beyond 4500. Nonetheless, this highly complex spectrum suggests promising 
future studies to distinguish higher order AT-FXa complexes on native heparin chains 
with more sophisticated ESI MS methods, such as limited charge reduction on FTICR 
MS.
171
  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Superimposition of ESI mass spectra of AT (1.8 μM) and FXa (1.5 μM) 
in the absence (black trace) and presence of native heparin (~2.4 μM) (red trace) at 
150 mM ammonium  acetate, pH 7.0. 
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5.4 Discussion 
 
ESI MS has advantages over other biophysical techniques to determine the 
stoichiometry of the multi-protein complexes, which exist in solution under 
equilibrium.
172
 In this study, we have investigated the effect of heparin chain length on 
mediation of complex formation between AT and FXa, which is an inhibitory event in 
coagulation. In this diffusion-controlled macromolecular reaction, an AT·FXa·Hp 
encounter complex forms prior to reaction.
173
 At the final step of the reaction, an AT·FXa 
covalent binary complex forms
174,175
 and heparin dissociates from the complex. Our ESI 
MS results demonstrated that the formation of the AT·FXa binary complexes is greatly 
enhanced in the presence of short heparin oligomers (dp ≤ 10). The AT·FXa binary 
complex signal was correlated with the concentration of heparin oligomer, as also 
suggested by the previous findings.
176
 In our studies, Hp oligomers were not detected as 
a part of the final complex, especially with dp6 and dp8, which could indicate that short 
heparin oligomers catalyzed the encounter and reaction completed faster. This 
observation could be in accordance with recent studies, in which short heparin oligomers 
were proven to be more efficient in catalyzing AT-FXa binding by  improving the 
conformational stability of AT.
161
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Figure 5.5: Proposed the reaction steps in diffusion-controlled AT, Hp and FXa 
interactions.  
 
In the presence of dp20, ESI MS clearly demonstrates that dp20 facilitates the 
formation of stable ternary AT·FXa·dp20 complexes. AT·FXa binary complexes were 
certainly absent from the spectra, as confirmed by the deconvolution analysis. One 
possible reason is that dp20 binds simultaneously to AT and FXa. This “reduction in 
dimensionality effect”33 is consistent with the previous observations for AT and thrombin 
interactions.
158,162
 While proteins are bound on the same chain, they might spend more 
time interacting and this might delay the formation of final binary covalent AT·FXa 
complex.  
 
 
 
 
 
 
 
Figure 5.6: Crystal structures for (a) AT-FXa-pentasaccharide and (b) AT-
Thrombin-heparin (18 monosaccharide length) 
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The other possibility is that dp20 exhibits higher affinity towards AT; therefore it 
does not dissociate from AT even after the reaction stage is completed. The higher 
affinity of dp20 compared to shorter heparin oligomers can be qualitatively assessed from 
the ESI MS spectra by the comparison of the relative abundance of free AT or AT-
heparinoid complex as a function of heparin oligomer chain length. The most dramatic 
difference can be seen in the case of dp20 binding, in which the AT·dp20 complex 
exhibits higher relative abundance compared to the shorter chains, even though the 
concentration of dp20 is half that of the shorter heparinoids. Specific Hp chains that 
facilitate the AT-FXa interactions are the main interest in pharmaceutical applications; 
however, the structural heterogeneity is such that the resolution of our experiments was 
not sufficient to determine the specific heparin oligomer species.  
5.5 Conclusions 
Short Hp chains (dp ≤ 10) promoted binary AT·FXa complexes and they most 
likely have improved the conformational stability of AT towards FXa to facilitate the 
reaction. On the contrary, dp 20 induced ternary AT·FXa·dp20 complexes, possibly by 
binding simultaneously to AT and FXa. Furthermore, higher affinity between AT and 
long heparin chains could be the reason that dp20 stays in the ternary complex longer. 
Native heparin chain could promote formation of higher order AT-FXa complexes, 
(possible 4:1) and this observation could be further supported by the future studies using 
limited charge reduction method in FTICR MS. This study also demonstrated (for the 
first time) the capability of ESI MS to resolve the complex stoichimetries between AT 
and FXa in the absence and in the presence of heparin oligomers.    
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 CHAPTER 6 
ANTITHROMBIN AND FULL-LENGTH HEPARIN COMPLEXES DETECTED 
ON FTICR MS BY LIMITED CHARGE REDUCTION 
Abzalimov, R.; Minsky, B. B.; Kaltashov, I. A. 
6.1 Introduction 
The preeminent challenge in the characterization of protein-heparin interactions is 
the immensely polydisperse heparin structure, which limits the application of various 
analytical techniques. Thus, the most common approach is to use heparin oligomers with 
a reduced-heterogeneity in protein interactions. Even though heparin oligomers have 
provided insights on the protein binding, the structural properties of these oligomers 
deviate from the biologically relevant full-length, “native” heparin (Hp). Electrospray 
ionization mass spectrometry (ESI MS) has emerged as a fundamental technique to study 
heparin oligomers and detect their non-covalent complexes; however correct mass and 
charge assignment is a major obstacle for the highly heterogeneous systems, especially 
for full-length heparin-protein complexes. We approached this problem using a recently 
evolved technique, limited charge reduction, in order to determine the complex 
stoichiometries between antithrombin (AT) and full-length heparin.   
Characterization of native heparin-protein complexes have been achieved using 
various analytical tools, such as light scattering,
134
 analytical ultracentrifuge,
125
 size 
exclusion chromatography.
177
 Even though these techniques provide size distributions of 
macromolecular complexes, deducing complex stoichiometry can be challenging due to 
the coexistence of multi-protein complexes in solution. In addition, these techniques 
provide average solution properties and do not provide detailed structural information. 
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ESI MS appears as a significant tool for the detailed structural information of the protein-
heparin complexes; however native ESI MS has not been fully implemented in this field 
so far. The applications have been limited to relatively homogeneous and shorter length 
heparinoids and their complexes with proteins.
88,178-181
  
The enhanced applicability of the short heparin analogs has generated concerted 
efforts to define the specific heparinoid structure in protein binding.
18
 However, this 
reductionist approach not only deviates from biological relevance, but also ignores the 
polyelectrolyte properties of heparin. In heparin-protein binding, long-range electrostatic 
forces and chain dynamics contribute significantly to the protein recognition and 
selectivity process.
139
 Therefore, there is a need for improved analytical tools to 
characterize native heparin-protein complexes in more detail and obtain structural 
information. ESI MS can be utilized for this purpose, but the challenges associated with 
the immense heterogeneity need to be addressed.  
A recently developed technique, limited charge reduction, mass-selects a narrow 
subpopulation of the ionic species in the highly heterogeneous spectra, which are then 
subjected to electron capture reactions to induce formation of well-defined charge 
ladders. The resulting charge state “ladder” can be used to calculate the mass of isolated 
complex ions. This method was successfully implemented to analyze highly 
heterogeneous systems, such as  glycosylated proteins
182
 , protein aggregates
183
 and 
protein multimers.
184
 AT-Hp interactions possess a great deal of interest due to the 
clinical usage of heparin in anticoagulation, but the studies so far have been greatly 
focused on the synthetic and short heparin mimetics to modulate AT binding.
168,185,186
 
The challenges associated with the heterogeneous native Hp can be overcome using 
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limited charge reduction to determine the AT-Hp complex stoichiometries in near 
physiological conditions.  
6.2 Experimental 
Human α-AT (MW = 57.8 kDa) was generously donated by CSL Behring 
(Marburg, Germany) and was purified from human plasma using heparin affinity 
chromatography. Full-length “native” heparin (Hp) was provided by John T. Gallagher 
(Iduron, Manchester, UK). AT and Hp solutions for ESI MS and FTICR MS analysis 
were prepared in 150 mM ammonium acetate to final concentrations of 1.8 μM for AT 
and 0.044 g/L, ca. 2.4 μM for Hp. Both nano-ESI Qstar-MS and FTICR MS show that 
the concentration of AT should not exceed 1.5 μM to prevent formation of AT multimers 
prior to Hp addition. ESI MS experiments were performed with a QStar-XL hybrid 
quadrupole-time-of-flight MS with a nano-ESI-source (AB Sciex, Toronto, Canada) and 
the measurements were performed using closed (2 μm id) glass nanospray capillaries 
(New Objective, Woburn, MA). Protein ion charge reduction was carried out with a 
SolariX 70 (Bruker Daltonics, Billerica,MA) Fourier transform ion cyclotron resonance 
(FTICR) MS. Ion isolation was done in the collision cell (up to 2 seconds of 
accumulation time) and electron capture was applied is in the ICR cell. Molecular weight 
distribution of full-length heparin was determined by SEC-MALLS (Wyatt) using 
TOSOH SW3000xl column to elute 1 g/L heparin sample with 0.1M NaCl. AT-Hp 
complexes were also determined by SEC using TOSOH SW3000xl column (mobile 
phase: 150mM ammonium acetate, pH 7.0). 
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6.3 Results and Discussion 
6.3.1 AT-native Hp complexes were obtained using native ESI MS and SEC 
AT is a highly glycosylated protein (58 kDa) with an approximately 15% 
carbohydrate content by weight.
187
 ESI mass spectrum of AT and native Hp indicates free 
AT monomer and AT-Hp complexes which appear in the range of 4500 < m/z < 6500 
(Figure 6.1a). There are two distinct regions representing AT-Hp ionic species; however 
both AT glycosylation and immense Hp structural heterogeneity give rise to a highly 
complex and unresolved mass spectrum. In this case, it is not possible to determine the 
exact mass and charge state distributions of these species due to overlapping ionic peaks 
representing different charge states.  
More evidence for the formation of AT-Hp complexes comes from SEC profiles 
as shown in the inset of Figure 6.1b. SEC results shows that approximately 50 % of AT 
monomer are depleted in the presence of Hp, and AT-Hp complexes form as shown by 
the appearance of the early eluting peak. The complex peak has a broad width, which can 
designate unresolved and various size AT-Hp complexes. Furthermore, the elution profile 
of the native heparin on SEC-MALLS demonstrated that the native heparin chains have 
an average mass of 18 kD with a 1.1 polydispersity index (Figure 6.1c). Both SEC and 
native ESI MS evidently show the formation of multiprotein complexes of AT and Hp, 
with a better resolution in ESI MS; however the limited charge reduction method is 
certainly needed to resolve the exact complex stoichiometries.    
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Figure 6.1: (a) ESI mass spectrum of AT (1.8 μM) and native Hp (0.044 g/L, ca. 2.4 
μM) acquired using nano-ESI Qstar-MS (at 150 mM Ammonium acetate, pH 7.0). 
(b) AT (0.4 g/L) and native Hp (0.2 g/L) complexes detected on SEC (c) Elution of 
native heparin on SEC-MALLS. 
 
6.3.2 Correct mass assignment of the AT-Hp complexes was achieved by limited 
charge reduction 
AT alone and AT-Hp mixture were also acquired on FTICR MS; however transfer 
optics of FT-ICR MS was optimally tuned to detect ions at higher m/z range ( >4000). 
Therefore, the intensity of the ionic species that represents AT-Hp complexes was more 
abundant in FTICR MS than nanospray ESI MS. Protein self association was not 
observed in the absence of Hp and the complex peaks were still unresolved due to the Hp 
polydispersity and overlapping charge states.     
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Figure 6.2: ESI mass spectrum of AT (1.8 μM) and native Hp (0.044 g/L, ca. 2.4 μM) 
acquired using FTICR MS (at 150 mM Ammonium acetate, pH 7.0). 
 
In the process of partial charge reduction, an isolated fraction of the Z
+
 charge 
state ions is mass selected in the collision cell width w0. When these selected ions are 
exposed to electron irradiation, they should produce charge reduced peaks and the widths 
can be assigned to w=w0*(Z/Z-K) on the m/z scale, where K represents the number of 
captured electrons. This approach was tested with the selection of m/z = 4580 (Figure 
6.3a) and m/z = 4740 (Figure 6.3b) and they both showed that the equation accurately 
estimates the widths of the charge reduced peaks (fitted with Gaussians in blue) based on 
the defined widths of isolated peaks (fitted with Gaussians in black). Deconvolution 
analysis reveals the mass distributions, which are ~73,180 Da in (a); ~75,820 Da in (b), 
corresponding to AT·Hp (1:1) complexes.  Therefore, it is quite reasonable to consider 
this method for reliable identification of charge reduced peaks in more challenging cases, 
which is shown in Figure 6.3c. The selection of m/z = 5200 yield two distinct 
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distributions: (1) 88, 489 Da (green trace), which correspond to AT·Hp2 (1:2) species, (2) 
135,510 Da (pink trace) which is assigned to AT2·Hp (2:1) complexes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: The results of partial charge reduction of mass-selected AT-Hp complex 
populations. Insets represent the convoluted mass distributions of the detected 
complexes. 
 
 
The mass distribution of Hp molecules in the AT·Hp complexes with 1:1 
stoichiometry are detected as 15 and 17 kDa (Figure 6.3a and 6.3b). On the contrary, Hp 
mass is 19 kDa in the AT2 ·Hp complex (2:1) indicating that two AT molecules are able 
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to bind to long Hp chains, which are approximately 33-mer (as the average mass of a 
disaccharide is assigned to 571 Da
10
). Intriguingly, AT·Hp2 (1:2) complexes were 
observed (Figure 6.3c), in which the total mass of bound two Hp chains are in the range 
of 25 to 30 kDa.  
Multiple heparin oligomer binding to AT has also been observed with shorter 
chains. Figure 6.4 shows ESI mass spectra of AT-dp10 complexes with increasing dp10 
concentration from (a) to (c), in which a progressive increase in the dp10 to AT bulk ratio 
leads to the formation of AT·(dp10)2 and AT·(dp10)3 complexes. Multiple dp10 bindings 
were achieved by using more than 25-fold higher concentration of dp10 over AT. On the 
contrary, AT·(Hp)2  complexes were observed when  native Hp molar ratio was 1.6-fold 
excess over AT.  This may indicate that the probability of finding the selective AT 
binding domain is higher with the native Hp chains. 
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Figure 6.4: ESI mass spectra of AT (~1 μM) and dp10 with dp10/AT mixing ratio (a) 
10, (b) 25 and (c) 50 at 150mM ammonium acetate, pH 6.8. Panel (d) shows the 
relative abundances of AT· (dp10)0, AT· (dp10), AT· (dp10)2 and AT· (dp10)3 
complexes with respect to bulk mixing ratio. 
 
6.4 Conclusions 
Unresolved ESI mass spectra of extremely heterogeneous AT and native Hp 
complexes were successfully analyzed by mass-selecting narrow ionic subpopulations 
followed by limited charge reduction in the gas phase. The resulting charge state 
“ladders” were used to calculate the mass of isolated protein ions; thus AT·Hp (1:1), 
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AT·Hp2 (1:2) and AT2·Hp (2:1) stoichiometric complexes were detected. Relatively 
shorter heparin chains were involved in 1:1 and 1:2 complexes, whereas longer Hp chains 
were able to induce 2:1 complex formation. This study indicated that the limited charge 
reduction method, complementary to native ESI MS, can be effectively used to obtain 
structural information from highly heterogeneous complexes of biopolymers. 
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CHAPTER 7 
INHIBITION OF ANTITHROMBIN AND BOVINE SERUM ALBUMIN NATIVE 
STATE AGGREGATION BY HEPARIN 
 
Minsky, B. B.; Zheng, B.; Dubin, L. P., Inhibition of antithrombin and bovine serum 
albumin native state aggregation by heparin. Langmuir 2013 
7.1 Abstract 
 Protein native state aggregation, a major problem in pharmaceutical and 
biological processes, has been addressed pharmacologically by the addition of protein-
binding excipients. Heparin (Hp), a highly sulfated polysaccharide, interacts with 
numerous proteins with moderate to high affinity, but reports about its effect on protein 
aggregation are contradictory. We studied the pH dependence of the aggregation of 
antithrombin (AT) and bovine serum albumin (BSA) in the presence and absence of 
heparin. High-precision turbidimetry showed strong aggregation for both AT and BSA in 
I = 10 mM NaCl, conditions at which electrostatically-driven Hp binding and 
aggregation both occur, with more obvious aggregation of heparin-free AT appearing as 
larger aggregate size. Aggregation of AT was dramatically inhibited at Hp: protein 6:1 
(mole ratio); however, the effect at 0.5:1 Hp: protein was greater for BSA.  Frontal 
analysis capillary electrophoresis showed a much larger equilibrium association constant 
Kobs between Hp and AT, in accord with the onset of Hp binding at a higher pH; both 
effects are explained by the higher charge density of the positive domain for AT as 
revealed by modeling with DelPhi. The corresponding modeling images showed that 
these domains persist at high salt only for AT, consistent with the 160-fold drop in Kobs at 
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100 mM salt for BSA-Hp binding. The smaller inhibition effect for AT arises from the 
tendency of its uncomplexed monomer to form larger aggregates more rapidly, but the 
stronger binding of Hp to AT does not facilitate Hp-induced aggregate dissolution which 
occurs more readily for BSA. This can be attributed to the higher density of AT 
aggregates evidenced by higher fractal dimensions. Differences between inhibition and 
reversal by Hp arise because the former may depend on the stage at which Hp enters the 
aggregation process and the latter on aggregate size and morphology.  
7.2 Introduction 
The effect of heparin (Hp) on protein aggregation would appear from the 
literature to comprise both promotion and inhibition. These conflicting results could 
reflect the problem of comparing different proteins with different levels of Hp affinity 
and different aggregation mechanisms, both dependent on solution pH and ionic strength. 
Native state aggregation could facilitate the study and interpretation of Hp effects, 
because protein surface is better conserved and formation of unfolded states minimized. 
Native state protein aggregation is driven by electrostatics, and the protein surface charge 
anisotropy regulates protein self-association mechanisms. Electrostatics also controls Hp-
protein binding to understand its effects on aggregation. There is a need to explain the 
possible linkage between electrostatically driven native state aggregation and Hp-protein 
binding.  It is of interest to establish whether this relation holds for “heparin-binding” 
proteins which exhibit different Hp-affinities, such as antithrombin (AT) and bovine 
serum albumin (BSA). Therefore, we studied the native state aggregation of AT and BSA 
and the roles of Hp in both aggregation and disaggregation processes, using ionic strength 
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(I) and pH as a probe to investigate protein self-association mechanisms and Hp binding 
affinities.  
The detection of GAGs in deposits of fibrillar aggregates in amyloid diseases 
initiated a number of conflicting hypotheses about the promotion/inhibition of the 
aggregation of amyloid forming peptides and proteins in the presence of GAGs. The 
enhancement of gelosin aggregation by heparin (Hp) was correlated with its sulfate 
content and MW.
188
 Both Hp and CS (chondroitin sulfate) appeared to promote Aβ 
peptide aggregation.
189
 On the other hand, while p25-α aggregated in the presence of 
stoichiometric amounts of low MW Hp (10-14 monosaccharides), excess Hp diminished 
its aggregation.
190
 Hp induces aggregation/ fibril formation of some proteins under 
certain conditions, but may have more ambiguous or even benign effects, depending on 
conditions, as observed for the prion protein.
191,192
 Injection of low molecular weight 
heparin suppresses AA amyloid deposition in mice
193
 , and even when fibrils are 
promoted by Hp are less toxic than the earlier forms of aggregates.
189,194-196
 Finally, 
inhibition of Aβ aggregation is reported for GAG-mimetic sulfated glycopolymers.197  
These conflicting reports of Hp effects on amyloidogenesis may arise because the 
point at which Hp enters the aggregation process can vary and is often not well defined. 
This suggests that effects of Hp could be better understood with systematic studies with 
folded proteins that include elucidation of self-aggregation mechanisms and identification 
of the aggregation stage influenced by Hp. The self-aggregation of folded proteins is 
mostly studied under “accelerated” conditions, such as high temperature198 and low 
pH;
199-202
 however these conditions generally lead, either intentionally or fortuitously, to 
formation of intermediate states of the native structure, and the contribution of these 
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states to the aggregation processes could be difficult to evaluate.
203
 The two proteins 
chosen for study here, AT and BSA, are examples of this; as both of them are commonly 
studied at elevated temperatures.
204-208
 In contrast, the influence of Hp on native state 
aggregation can be more amenable to modeling;
209
 therefore consistent with general 
rules; because the hydrated protein surface is retained, and formation of intermediate 
states can be minimized.  The charge distribution on this surface, which plays a central 
role in inter-protein interactions,
124,133
 is controlled by protein structure and pH.  
Although native state protein aggregation is most readily seen at pH ~ pI 
(“isolectric precipitation”), its suppression by added salt indicates the primacy of 
electrostatic attraction.
210
 The central role of inter-protein surface interactions makes such 
aggregation amenable to colloid models, in which the aggregation kinetics could 
determine the aggregate structure. Aggregation follows formation of clusters from 
monomers, and growth could follow particle-cluster or cluster-cluster, and formation of 
these could be limited by diffusion.
211
 As shown in previous work,
 22,25
 protein charge 
anisotropy dictates the balance of attractive and repulsive electrostatic interactions that 
leads to one or more of the preceding aggregation mechanisms, which then control 
aggregate structure. The charge anisotropy of proteins also controls their interactions with 
Hp,
31
 and this suggests an implicit linkage between heparin-suppression and electrostatic 
aggregation.
209,210
 For example, Hp inhibits native state aggregation of BSA and BLG, 
with the inhibitory effect depending on charge-induced Hp-protein binding affinity.
209
 
Beyond affinity, the stage at which Hp enters the aggregation process plays an important 
role: inhibition of the aggregation of native state insulin seems to be enhanced when Hp 
is added after aggregation has begun.
210
 The availability of Hp-binding domains is 
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evidently subject to alterations in protein conformation.
212
 In the present work, we avoid 
contributions of protein unfolding by selection of conditions and proteins by on two 
stable proteins, AT and BSA. 
Heparin-protein binding affinity arises principally from polyelectrolyte-protein 
electrostatic interactions,
44,45
 for which different models have been widely applied. One 
model, inspired by theories for the salt dependence of oligolysine-DNA interactions,
46,47
 
has also been applied to DNA-protein binding. The linear dependence of log Kobs 
(equilibrium association constant) on log I (ionic strength) is consistent with a purely 
entropic Gobs which arises from the release of DNA counterions. However, directly 
replacing oligolysines with proteins fails to consider the influence of protein charge 
anisotropy.
48
 Nevertheless, extension of this treatment to Hp-protein binding yields a 
physically realistic value of Hp structural charge density deduced from measured 
dlogKobs / dlog I.
49
 On the other hand, many polyelectrolyte-protein systems show clearly 
different salt dependence, more consistent with Debye-Hückel screening.
44,50
 This model 
takes into account protein charge anisotropy, and effectively explains for the non-
monotonic salt dependence seen when polyelectrolytes (e.g., heparin) bind to proteins 
with net charge of the same (i.e. negative) sign, through a domain of opposite (i.e. 
positive) charge. This domain is best identified through representation of protein charge 
calculations.
51
 Therefore, it is possible to account for the observed salt dependence of 
protein-Hp binding by using specific models of heparin binding along with quantitative 
protein visualization.
28,51
  
The way in which Hp inhibits protein aggregation depends on Hp-protein binding 
affinity, and the stage at which Hp enters the aggregation process. The ability of Hp to 
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reverse aggregation depends also on aggregate structure. Resolution among these effects 
has not been achieved because variables such as pH and ionic strength influence both the 
mechanism and rate of aggregation, and the interaction of Hp with either aggregates or 
free proteins.  Protein charge anisotropy could in fact enhance both inter-protein and Hp-
protein interactions. Systematic studies of pH and ionic strength effects on appropriately 
selected aggregating and heparin-binding proteins are needed to elucidate these primarily 
electrostatic effects. Also, further insight into the effect of heparin on protein solubility 
could help guide the extensive but largely empirical use of polyelectrolyte precipitation 
for protein purification.
213-215
 
In order to elucidate the way in which the anti-aggregation effect of Hp is 
influenced by protein self-association and Hp affinity, we examine two Hp-binding 
proteins, Hp-cognate AT and non-cognate BSA. The literature clearly indicates larger 
rates of aggregation for AT than for BSA,
205
 although perspectives on their mechanisms 
of aggregation differ.
205,216
 In our work, native states have been preserved; therefore the 
behavior of the proteins is determined by its (hydrated) surface For this reason, general 
rules about aggregation (e.g. “isoelectric precipitation”) can be put forward, in contrast to 
unfolding aggregation in which any or all residues may contribute to a wide variety of 
interactions involving many intermediates. We used high-precision turbidimetry to assess 
both aggregation rates and Hp-affinity, and dynamic light scattering (DLS) to determine 
the size and the relative intensity of the aggregates as a function of pH and ionic strength. 
The fractal dimensions of the respective aggregates were measured by static light 
scattering. Electrostatic protein modeling was used to visualize domains of positive 
charge and to rationalize both aggregation and Hp-binding.   
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7.3 Experimental 
7.3.1 Materials 
Human recombinant AT (ATyrn, 58 kDa, pI ~ 5.0) was generously donated by 
GTC Biotherapeutics (Framingham, MA). Bovine Serum Albumin (BSA, 66 kDa, pI ~ 
4.9) and Heparin (Hp), with nominal MW 14 kDa, were purchased from Calbiochem and 
Sigma, respectively.  
7.3.2 Methods 
7.3.2.1 Turbidimetry  
High-precision turbidimetry was performed using a Brinkman PC800 digital 
display probe colorimeter equipped with a 1cm path length probe (at 420 nm), integrated 
into a system of our own design which is programmed for (1) automated constant 
delivery of selected titrant volume via a 2 mL Gilmont microburette at selected rates of 
addition, (2) selection of the number of percent transmittance (% T) and pH readings to 
be averaged, and (3) choice of the terminal pH.  The data were reported as τ = 100 - %T, 
which is unitless and linear with the turbidity over a certain range of transmittance. AT 
(0.25 g/L, 10 mL total volume) and BSA (1g/L, 10 mL total volume) solutions were 
prepared at desired NaCl concentrations (10-50 mM), filtered (0.22 μm Millipore), and 
titrated with either 0.1 N HCl or 0.1 N NaOH. AT-Hp and BSA-Hp mixtures were 
prepared by 1:1 v/v mixing of AT/BSA and Hp stock solutions (0.5 g/L) at a non-
interacting pH 8.5 (± 0.2). All measurements were done at ambient temperature. The 
precision in the volume of titrant added is typically ±2 ppt (0.2 %). The ability to average 
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multiple readings leads to transmittance measurement with a precision of 0.1 %T (±1 
ppt). 
7.3.2.2 Dynamic Light Scattering (DLS) 
DLS measurements were made after filtration (Millipore 0.22 μm) using a 
Malvern Instruments Zetasizer Nanosystem ZS, operating at 173º scattering angle with a 
633 nm He−Ne laser, at 25 °C. The measurement duration was 10-12 s. The distributions 
of the mean apparent translational diffusion coefficients (DT) were determined by fitting 
the DLS autocorrelation functions using nonnegative constrained least-squares (NNLS). 
The distribution of apparent hydrodynamic diameters Dh was obtained from the 
distribution of mean apparent translational diffusion coefficients (DT) via 
T
h
D
kT
D
6
2
    Eq. 7.1 
where k is the Boltzmann constant and η is the solvent viscosity, taken as that of water.  
Sample transfer and automated optimization steps result in a delay of 2−3 min. between 
initial pH adjustment and the first measurement. 
7.3.2.3 Static Light Scattering (SLS) 
SLS experiments were performed using a BI-200 SM goniometer and BIC-2030D 
photon counting system (Brookhaven Instruments Inc.) with an Omnichrome Ar ion laser 
(100 mW, λ = 488 nm) at ambient temperature, 25 °C. The scattering intensity was 
measured as a function of scattering angle between 45 and 130°. Fractal dimensions (Df) 
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were extracted from angle dependence in the high-q limit via linearization of the 
scattering data using the relation: 
Df
qqI )(               Eq. 7.2 
where I(q) is the scattering intensity and the scattering vector q = (4πn/λ) sin (θ/2), with n 
the refractive index of the fluid, λ the wavelength, and θ the scattering angle. The radius 
of gyration (Rg) was obtained using Guinier relation at relatively low-q region:  
3
)0(ln()(ln(
22
g
Rq
IqI   Eq. 7.3 
7.3.2.4 Computational Methods 
 DelPhi V. 4r1.1
130,131
 was used to model the electrostatic potential around the 
protein as a function of ionic strength.  PDB id is 3V03 and 2B4X were taken from 
protein data bank (http://www.rcsb.org/) for BSA monomer and AT monomer, 
respectively. The charges of amino acids on the proteins were determined using the 
spherical-smeared charged model put forward by Tanford.
132
 
7.4 Results 
7.4.1 Protein aggregation: effects of pH  
7.4.1.1 AT shows higher turbidimetric rates of aggregation 
Figure 1 shows the increase in 100 - %T in the range 4 < pH < 7 upon addition of 
acid to 1 g/L BSA in 10 mM NaCl.  A reduced concentration of 0.25 g/L was used for the 
more rapidly aggregating AT in order to maintain 100 - %T < 20. In this range 100 - %T 
is linear with the true turbidity τ = - log T, and can be most readily identified with the 
110 
 
accumulation of soluble aggregates.
217,218
 The pH for the onset of aggregation is 
qualitatively seen to be about 1 pH unit above pI for AT, in contrast to BSA for which pI-
pH = 0.5. Since protein concentrations are not the same, the difference in absolute values 
of τ is handled by comparing the turbidimetric rates of aggregation (dτ/dt)pH. This is 
calculated as (dτ/dpH) (dpH/dt), where (dτ/dpH) is obtained from Figure 1, and dpH/dt is 
automatically recorded at every pH.  In the resultant plot (inset of Figure 1), (dτ/dt) pH = 0 
would correspond to a maximum. This indicates equal turbidimetric rates of aggregation 
and disaggregation.
218,219
 The maximum rate of aggregation (d /dt) pH
max
 is seen at pH 6 
and 5.5 for AT and BSA, respectively. For BSA, the native state is preserved over a wide 
range of pH encompassing the experimental conditions here.
220-222
 For AT, there are 
additional suggestions of partial unfolding,
223
 but not at pH~6 as used here. Those studies 
refer to the dynamics of loop expulsion, presumably at a time scale that is not relevant to 
our measurements of relatively slow aggregation.  
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Figure 7.1:  Automated turbidimetric titrations of 0.25 g/L AT (red) and 1 g/L BSA 
(black) in 10 mM NaCl with the addition of 0.1 N HCl. Inset: Aggregation rate 
(dτ/dt) vs pH obtained from Figure 1 for AT (red) and BSA (black). 
7.4.1.2 Time dependence of AT and BSA aggregation can reveal aggregation 
mechanisms 
Figure 7.2 shows time dependent turbidities for AT and BSA under concentration, 
ionic strength and pH conditions in the vicinity (d /dt) pH
max
 in Figure 7.1. Since cAT / 
cBSA = 0.25, we focus on mechanistic differences, which are independent of protein 
concentration. In Figure 7.2, the turbidity reaches a limiting value for AT and BSA at 
similar times, with a larger limiting value for the former. The turbidity of AT increases 
rapidly for t < 1.5 min ( Figure 7.2 , inset (a) ), while the curve for BSA exhibits only a 
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small decrease in curvature at  t = 25 min. Figure 7.2 inset (b) compares the aggregation 
kinetics of AT and BSA using first-order plots obtained from the data in Figure 7.2.  The 
analysis of turbidity data in this way can be described as:
224,225
 
)1(
kt
e     Eq. 7.4 
where τ∞ is the limiting turbidity value at t = ∞ and k is the apparent rate constant.  
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2: Turbidimetric measurements in 10 mM NaCl for the time dependent 
aggregation of 0.25 g/L AT at pH 6.1 (red) and 1 g/L BSA at pH 5.4 (black). Samples 
were prepared at high pH (~ 8.5) and then brought to the desired pH within 3 min. 
using 0.1 N HCl. Inset (a): Expanded time scale for the first 16 min. Inset (b): First 
order fit for the time vs τ (100-%T)  in for AT (red) and BSA (black) in the first 7 
min. 
 
The first order appearance of the aggregation kinetics may indicate the 
mechanisms of aggregation for both proteins (vide infra). The evolution of aggregates 
was also probed with DLS (Figure 7.3) in the absence and presence of Hp (the latter will 
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be explained below). Contrary to turbidimetry, DLS cannot capture the first 2 min. due to 
the time lag between the sample pH adjustment and measurement, but provides a better 
molecular view, as seen in Figure 7.3 (a), in which cAT  =  cBSA  = 1 g/L. The experimental 
lag time, notwithstanding the rapid increase in turbidity for AT can be related to the 
increase in cluster size, from < 100 nm to 300 nm during the first 15 min. Two 
differences appear in Figure 7.3 (b) for BSA: the fast mode broadens as opposed to losing 
intensity; and the slow mode size increases by only a factor of 2.5, from 25 nm to 65 nm. 
The larger apparent initial rate from turbidity for AT appears to be due to rapid increase 
in aggregate size (Figure 7.3(a)) at the end of which the fast mode (monomer) no longer 
dominates the scattering intensity (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3: Time dependence of particle sizes by DLS in 10 mM NaCl in the absence 
and presence of Hp: (a) 1 g/L AT and 1 g/L AT with 0.1 g/L Hp (●) at pH 6.2 (b) 1 
g/L BSA and 1 g/L BSA with 0.1 g/l Hp (●) at 5.4 
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7.4.2 Effect of heparin on protein aggregation 
7.4.2.1 Heparin suppresses aggregation of both proteins  
Figure 7.4 shows inhibition of AT and BSA aggregation in the presence of Hp at 
various Hp:protein ( r ) ratios. The inhibition of aggregation by Hp can be observed only 
in the “pH window” bounded by formation of the heparin-protein complexes. At r = 0.1, 
the stoichiometry best suited for comparison of BSA and AT, the suppression of the 
aggregation is more pronounced for BSA. This is confirmed by DLS results (Figure 7.3), 
in which data in the absence of Hp are combined with results in the presence of Hp 
approximately 15 min.  after pH adjustment (this time lag leads to a small increase in Rh 
for the slow mode for AT alone, and to an increase in fast mode Rh for BSA alone). Here, 
we see that the fast mode intensity of the free monomer (or in the case of BSA, 
monomer-dimer) never exceeds 50 % for AT, but the fast mode is always the dominant 
scatterer for BSA. A separate but related effect is the concentration of monomer or 
monomer/dimer in the presence of Hp, obviously dependent on both the Hp-protein 
binding affinity, and the Hp:protein ratio r. At r = 0.1, the doubling of the apparent size 
corresponding to the fast mode for AT can only be explained by the conversion of AT 
monomer to its complex with Hp. In contrast, the fast mode for BSA at r = 0.1 
consistently exhibits an apparent size equal to that of the BSA dimer, regardless of time; 
BSA-Hp complexes and possibly BSA dimers coexist at that condition.  
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Figure 7.4: Inhibition of 0.25 g/L AT and 1 g/L BSA aggregation by heparin at 10 
mM NaCl. Heparin to AT weight ratio is (r) is 0.1 and 0.4 and heparin to BSA 
weight ratio (r) is 0.1 and 1. 
7.4.2.2 AT-Hp binding less sensitive to salt 
In order to evaluate the AT-BSA binding strength, we investigated the effect of 
salt concentration on the onset of Hp-protein complex formation (Figure 7.5). This event, 
pHc experimentally defined by a transition from a region of zero slope, reflects a 
reversible, equilibrium phenomenon as opposed to the purely or partially kinetic behavior 
described in all earlier Figures.  This critical pH qualitatively represents the condition at 
which the energy of complex formation just exceeds thermal energy, kT. When pHc 
appears on the “wrong side of pI” (here when global protein charge is negative), (pHc – 
pI) ≡ pH becomes a qualitative measure of the ability of binding to overcome this global 
repulsion. Although AT and BSA have similar pI values (4.9 and 5.0), pH is larger for 
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AT at all ionic strengths. Addition of salt lowers  for both AT and BSA, but the effect is 
more pronounced for BSA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5: Turbidimetric titrations of   AT (red), BSA (black) (0.25 g/L) and Hp 
(0.025 g/L) at 10, 20, 50 mM NaCl, using 0.1 N HCl.  Red and black broken lines 
were used to indicate the pHc values for AT and BSA, respectively. 
7.4.2.3 Hp cannot reverse AT aggregation, but can partially reverse BSA 
aggregation 
The inhibition of AT and BSA aggregation in the presence of Hp is a result of 
soluble complex formation between protein and Hp. Hp may also interact with the larger 
aggregates dissolving them into small intra-polymer complexes
209,210
 and in some cases 
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larger inter-polymer soluble species.   Figure 7.6 shows the results for AT and BSA upon 
addition of Hp to a protein:Hp ratio r  = 1 (w:w). The addition of Hp partially re-
dissolves BSA aggregates (at pH 5.3) but does not reverse the aggregation of AT (at pH ~ 
6.1). 
 
 
 
 
 
 
 
 
 
 
Figure 7.6: Reversal of aggregation in 10 mM NaCl (a) 0.1 g/L AT and (b) 1 g/L 
BSA by the addition of Hp (r = 1). Both protein solutions were prepared at pH 8.5 
and pH was adjusted to 6.1 for AT and 5.3 for BSA within 3 min. using 0.1 N HCl. 
Solutions were kept for 20 min. at room temperature prior to Hp addition.  
 
7.5 Discussion 
7.5.1 AT and BSA aggregation mechanisms are different  
The result for AT in the Figure 7.2, inset (b), which shows the first order fit of 
turbidity vs time, is in agreement with  nucleation (rapid initial consumption of monomer 
to form well-defined clusters) and growth (addition of monomer to these clusters), the 
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first step difficult to observe for BSA. The initial AT cluster size could not be identified 
because of the time lag for DLS which can only identify after 4 min. a 100 nm species for 
AT (Figure 7.3 (a)), and a 25 nm species for BSA (Figure 7.3 (b)). In the first 15 min., 
the rate of depletion of the AT monomer is slightly faster than that of monomer/dimer 
(BSA). There are two possible routes for the increase in turbidity over long times: 
clusters either grow by association (“cluster - cluster”), or by adding monomer/dimer 
(“growth”).224 The first-order appearance of the curves in Figure 7.2, inset (b) for both 
proteins suggests that aggregates grow by the latter route. The transition from fast to slow 
steps, seen after 2 min. for the aggregation of AT, resembles that of BLG at pH near pI 
and in low salt. This protein also exhibits diffusion limited particle-cluster aggregation as 
a second step.
219
  
A notable difference between AT and BSA aggregation is seen in the evolution of 
the fast mode in Figure 7.3 (b) for BSA, which in contrast to AT, broadens and shifts to 
larger Rh with time. While Rh confirms to the AT monomer radius (4 nm) at all times, Rh 
increases from 5 to 8 nm for BSA in the interval 3-14 min., accompanied by peak 
broadening. We interpret these results as depletion of BSA monomer from the monomer-
dimer pool, with the concentration of monomer then determining the rate of cluster 
growth, as opposed to cluster-cluster association. For AT, all un-aggregated protein is 
present as the 4 nm monomer, and cluster growth is more rapid. 
The absence of cluster-cluster association for both proteins can be explained by 
their net charge at pH-pI > 0. However, the interaction of negatively charged AT 
monomer with negatively charged clusters is ameliorated by the charge anisotropy of the 
AT monomer as depicted in Figure 7.7. This same charge anisotropy also enhances 
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monomer-monomer association kinetics and thus the rate of nucleation; this accounts for 
the nucleation step probably present for both proteins, but more readily detected for AT. 
Therefore, the greater charge anisotropy (see Figure 7.9) enhances the rate of 
nucleation.
218
 The role of charge anisotropy of the BSA monomer is further complicated 
by its equilibrium with the dimer, as evidenced by the wide range of Rh values seen for its 
fast mode in Figure 7.3 (b). The increase from 5 to 7.5 nm during the first 10 min. of 
aggregation can be best explained as the depletion of monomer through its preferential 
aggregation. In that sense, dissociation of dimer exerts some control over the rate of 
aggregation. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7: Models for the aggregation pathways of AT and BSA.  
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7.5.2 Inhibition of aggregation is a result of competition between Hp binding and 
self-aggregation 
The magnitude of heparin inhibition is qualitatively assessed by comparison of 
turbidimetric titrations with and without Hp for the two proteins. As shown in Figure 4, 
the inhibition effect depends on the heparin concentration (or bulk weight ratio r). 
Together with the protein-Hp binding affinity, this stoichiometry controls the fraction of 
protein that forms complex, and thereby controls the aggregation rate by modulating the 
free protein concentration. The assumption is that heparin-protein complexes have no 
direct influence on aggregation kinetics. At equal r = 0.1, the concentration of total 
protein is 4-fold smaller for AT than for BSA, but the intrinsically rapid aggregation of 
free AT results in larger turbidity.  
Evidence of the depletion of protein monomer upon addition of Hp should emerge 
from DLS. In Figure 7.3 (a), AT monomer (Rh = 4 nm) is well resolved from complex at 
Rh = 8.5 nm, and is seen to be fully converted to a mixture of small and large complexes 
in the presence of Hp. BSA aggregate clusters vanish in the presence of Hp (Figure 7.3 
(b)) but the ca. 8 nm complexes cannot be well resolved from BSA monomer/dimer. BSA 
monomer/dimer persists in the presence of Hp because of its relatively low Hp affinity; 
but BSA aggregates fail to form. The effect of Hp on BSA aggregation relative to its 
weaker effect on AT aggregation, may be related to the differences in aggregate or 
aggregation mechanism, most notably the presence of an obvious nucleation step for AT. 
The amount of Hp required for suppression is r = 0.1 for BSA and r = 0.4 for AT. The 
larger requirement for AT suppression despite its stronger binding is a reflection of the 
strong tendency of its monomer to aggregate even at lower concentration. The second 
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effect of r is the shift of pHφ to lower pH.
209
 This phase separation occurs when 
complexes achieve charge neutrality. When the ratio of Hp to protein is large, each Hp 
binds few proteins, and the positive charge per protein needed to overcome Hp charge is 
large, which corresponds to low pHφ.  
7.5.3 Stronger binding of Hp to AT, notably at high salt, manifested as high values 
of pHc 
We proceed to interpret the results of Figure 5 in terms of binding constants for 
Hp-BSA and Hp-AT measured elsewhere. The ionic strength dependence of pHc shown 
in Figure 7.8 (a) provides a qualitative comparison of Hp affinity for AT vs BSA: the 
expanded domain of complexation seen for AT indicates its stronger heparin binding. 
Corresponding measurements by FACCE
28,51
 verifies this more quantitatively, and both 
measurements show that the difference in Hp affinity between AT and BSA strongly 
increases with added salt (Figure 7.8 (b)). Interestingly, the frequently noted linear log-
log dependence of Hp-protein binding
17
 is seen to apply only at I > 10 mM for BSA and 
25 mM for AT.  
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Figure 7.8:  (a) Ionic strength dependence of pHc obtained from turbidimetry (from 
Figure 7.5). The dashed lines are drawn to guide the eye. (b) Ionic strength 
dependence of the binding constant obtained by FACCE. The data for BSA and AT 
from ref. 51 and ref. 28. 
 
The differences between BSA and AT in Figure 7.8 can now be explained by the 
charge distributions of the two proteins as represented by DelPhi images (Figure 7.9). 
The maximum in the plot for AT has been interpreted in terms of combined attractive and 
repulsive forces,
28
 which should be more important for AT because of its charge 
anisotropy. The more pronounced positive domain for AT leads to the formation of an 
AT-Hp complex that is more salt resistant than the BSA-Hp complex. This is also 
reflected in the persistence at high salt of the positive (Hp-binding) electrostatic domain 
of AT, and the virtual disappearance of this domain for BSA at 100 mM salt, entirely 
consistent with the drop in log K at log I = -1 for BSA in Figure 7.8 (b).  
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Figure 7.9: Ionic strength dependence of the electrostatic potential contours at - 0.5 
kT/e (red) and 0.5 kT/e (blue) for AT and BSA at pH 6.0. 
 7.5.4 Aggregate fractal dimensions larger for AT than for BSA 
The greater charge anisotropy for AT vs. BSA is not only consistent with its 
stronger Hp binding, but may also explain the inability of Hp to reverse AT aggregation 
as shown in Figure 7.6.  This apparently contradictory relation, the resistance to Hp-
induced dissolution is greater for the protein with higher Hp affinity, can be understood 
in terms of aggregate formation and density.  Recent Monte Carlo simulations have 
contrasted the aggregation behavior of uniformly and non-uniformly charged colloids, in 
which the latter interact more strongly and form larger clusters.
226
 While both proteins 
here exhibit charge anisotropy, AT more nearly resembles the extreme case of non-
uniform charge with correspondingly strong short-range attraction. This is expected to 
lead to a densely packed aggregate, resistant to dissolution. The binding of Hp as an 
inhibitor of aggregation can be considered energetically in terms of the equilibrium 
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between complex and free protein, reducing its concentration and thus lowering the rate 
of aggregation. The stabilization of the former might be considered to arise from multiple 
interactions of the flexible Hp chain with the protein. Similar considerations have been 
referred to as “multivalency”, but this does not reflect the role of polyelectrolyte chain 
dynamics. Aggregate dissolution follows a different path involving Hp diffusion onto and 
into aggregates, and a variety of subsequent kinetically controlled steps which cannot be 
readily identified by the current methods.  The structure of the aggregate may play a role 
at least as significant as the intrinsic protein-Hp molecular affinity discussed above.   
To support this latter hypothesis, fractal dimensions of AT aggregates were 
determined by static light scattering (Figure 7.10) and compared to published results for 
BSA. The difference between Df (AT) = 2.3 ± 0.1 (Figure 7.10 (c)) and 1.7 (BSA)
227
 
supports the argument that the greater density for AT aggregates makes them impervious 
to dissolution by Hp. However, when Hp is initially present with AT at pH 8 and r = 0.1 
(prior to adjustment to pH 6.1) similar SLS measurements lead to Df (AT-Hp) = 0.8 ± 
0.1, consistent with a highly extended rod-like chain. Since AT is net-negative at this pH, 
both steric and electrostatic effects lead to intra-polymer repulsion in the Hp-AT complex 
and consequent chain stiffness. To our knowledge, this is the first reported measurement 
of the fractal dimension of an Hp-protein complex. Nominally, the values of Rg / Rh are 
0.8 and 0.9 for aggregated AT and AT-Hp complex, respectively from the Guinier plot 
shown in Figure 7.10 (b). The former, very close to the limiting value for spheres, is 
consistent with the large value of Df, but the latter is not consistent with the extended 
conformation deduced from Df = 0.8. These ratios must be considered in the light of the 
averaging of signals from large and small scatterers for both systems, unavoidable for 
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SANS and arbitrary for DLS. These averages tend to be weighted more toward the 
smaller species in Malvern due to backscattering. More accurate results will require angle 
dependence of diffusion coefficients complementary to Figure 7.10 (a).  
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Figure 7.10: SLS of 1 g/L AT and 1 g/L AT and 0.1 g/L Hp (r = 0.1) in 10 mM NaCl, 
pH = 6.2 (a) Scattering intensity (I) as a function of scattering vector (q), (b) Guinier 
plot to determine Rg in the low-q region and (c) High-q region to determine fractal 
dimensions of AT aggregates and AT-Hp complex. 
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7.6 Conclusions 
Heparin (Hp) inhibits and reverses aggregation more completely for BSA than for 
antithrombin (AT). Since heparin binds more strongly to AT, this difference is not due to 
the conversion of protein monomer/dimer to non-aggregating complex, which would be 
greater for Hp. The reduced effects of heparin for AT occur because the relatively low 
concentration of uncomplexed AT monomer aggregates far more extensively than the 
more abundant BSA monomer/dimer. The values of pH at which complexes are first 
observed at different ionic strengths, relative to pI a measure of the ability of binding to 
overcome repulsion between heparin and global protein charge -- is in good qualitative 
agreement with measurements of binding constants by FACCE. These two measures of 
protein-heparin affinity are shown to be consistent with protein charge anisotropy as 
revealed by electrostatic modeling. In contrast to inhibition, the reversal of protein 
aggregation by heparin is also influenced by aggregate structure: the low fractal 
dimensions of BSA aggregates make them more susceptible to dissolution mediated by 
heparin binding.  
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CHAPTER 8 
CONCLUSIONS AND FUTURE STUDIES 
We have investigated the effects of heparin charge density and chain length in 
protein binding taking into account both polyelectrolyte properties of heparin and 
electrostatic interactions between heparin and protein. Charge complementarities between 
the protein surface and heparin were found to play significant roles in the protein 
recognition process. In addition, conservation of heparin chain dynamics in the bound 
state lead us to consider a more nuanced “specificity” and “selectivity” of heparin in 
protein binding, as opposed to the classical “lock” and “key” type interaction, in which 
heparin is thought to have specific conformation in order to bind to a well defined epitope 
on the protein surface. 
Our studies showed that heparin is subjected to counterion condensation, and the 
degree of condensation exhibits an inverse relation with chain length, which is due to the 
diminished condensation at the chain ends. The remarkable success of the simplified 
model (as presented in Figure 2.6) to establish effective charge calculations for heparin 
oligomers, in which each sulfate group is treated as the same, could indicate the 
significance of overall sulfation, rather than precise sulfate locations to define heparin 
chain properties. Contrary to Hp, HS structure is comprised of well-defined low (NA) 
and high sulfation (NS) domains; therefore, the junctions could lead to preservation of the 
high effective charge density of NS domains by inhibiting counterion condensation. This 
hypothesis could be tested by measuring the elecrophoretic mobility distributions of HS 
oligomers and compare them with the heparin oligomer mobilities. The preservation of 
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the HS high effective charge density could be significant in mediating growth factor 
binding on the cell surface.  
The contribution of counterion condensation in heparin/HS-protein interactions, 
i.e. the significance of effective charges as opposed to structural charges in protein 
binding, is not well understood. It has been proposed that heparin-protein binding is 
analogous to DNA-oligolysine interactions, in the sense of being driven by the entropy of 
expelled counterions. In this case, an increase in the effective charge of the protein-
binding domain on HS could amplify the binding constant in comparison to heparin.  
This hypothesis could be tested by measuring the apparent association constants between 
FGF (or AT) –HS and Hp oligomers using frontal analysis capillary electrophoresis 
(FACCE). If the effective charges are the major determinants for protein binding, we will 
observe higher association constants with HS compared to Hp.   
Highly sulfated heparin oligomer chains were able to induce the formation of 
multimeric complexes of FGF. This observation could demonstrate that these highly 
sulfated chains might have the optimal binding sites, i.e. properly arranged charged 
segments, compared to the lower sulfated chains. The sulfation pattern could be 
determined by isolating bound Hp/HS oligomers using size exclusion chromatography or 
capillary electrophoresis, and the isolated Hp/HS fractions could be further sub-
fractionated using strong anion exchange chromatography. Then, these sub-fractions 
could be sequenced using ESI MS fragmentation methods such as collision-induced 
dissociation (CID) or electron detachment dissociation (EDD).  Complementary to ESI 
MS, Monte Carlo simulations can be applied in FGF and heparin oligomer interactions in 
order to elucidate the structural selectivity of Hp/HS. Monte Carlo simulations could 
130 
 
enable identifying the Hp/HS configurational flexibility at the protein-bound state, and 
also calculate the binding energies for the high and low affinity Hp/HS oligomers which 
were identified from the prior ESI MS studies. These concerted efforts of elucidating 
affinity, structural charge distribution, and the chain dynamics of HS/Hp could provide a 
better understanding of the selectivity and the plasticity of protein-HS/Hp interactions.  
The convergence of ESI MS and simulation studies in order to determine HS/Hp binding 
motif could build confidence to employ longer HS/Hp oligosaccharides in growth factor 
interactions. The complementarities between protein surface charge and detected HS/Hp 
binding motifs could be used to predict the relative affinities of various protein-Hp/HS 
pairs, which could explain how Hp/HS provide binding sites for a multitude of proteins. 
The incorporation of well-defined heparin oligomers into biomedical scaffolds is 
a new approach in tissue engineering. In our model system, heparin decamer (dp10) 
could bind both tetralysine (K4) and a growth factor (FGF1). Tetralysine is bound in 
regions rich in condensed counterions, as opposed to chain ends, and the binding of a 
single tetralysine, which still leaves “space” for FGF to bind, is significantly weaker than 
the binding of FGF. An alternative approach, more relevant to tissue engineering 
applications, would be an examination of longer Hp chains where the ratio of condensed 
counterions to structural charges would be larger, so that binding of oligopeptide and 
FGF on the heparin oligomer chain could be more competitive. Cationic biopolymer 
chitosan is an alternative for oligopeptide as a scaffold material because chitosan has a 
high degree of biocompatibility andbiodegradability, its chemical structure can be easily 
modified, and it form complexes with heparin. Heparin-chitosan complexes can be used 
as a platform for growth factor delivery, and using oligoheparins and oligochitosans, as 
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opposed to native heparin and high molecular weight chitosan, could provide a better 
control for growth factor capture and release due to the reduced heterogeneity. The 
binding of oligoheparin to low-charge density chitosan could be weaker than growth 
factor-heparin oligomer binding; however the extent to which oligochitosan interferes 
with growth factor binding should be elucidated. Therefore, the ternary complex 
formation between heparin oligomers, oligochitosans and growth factors can be 
investigated using ESI MS at varying ionic strength and pH values. 
Monte Carlo simulations could also be used to propose interaction mechanisms 
for FGF-Hp and AT-FXa - Hp interactions taking into account our ESI MS results. 
Monte Carlo simulations showed that a small portion of the Hp mimetic interacted with 
FGF at any time. This result could be used to assess the mechanism of three FGF 
molecules binding to Hp decamer chain, in which three FGF molecules may be bridged 
by heparin oligomer with transient interactions. This observation may raise a possibility 
for their catalytical roles in growth factor binding, which has also suggested in AT 
interactions with coagulation proteases. Our ESI MS studies indicated that short Hp 
chains (dp ≤ 10) promote binary AT·FXa complexes. Shorter Hp chains may transiently 
bridge the positive domains of AT and FXa, but that the most favorable orientation of AT 
and FXa may no longer need that bridge. Thus, Monte Carlo simulation could be 
employed in AT, FXa, and short heparin chain (dp ≤ 10) binding to probe the dynamics 
of the polymer and its ability to stabilize AT-FXa complex.  This could provide a better 
understanding of how short heparin chains catalyze the formation of binary complex and 
at what stage heparin oligomer dissociates from the complex.  
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The resultant AT-FXa complex has been suggested as covalent, and this covalent 
nature of can be further investigated either with MS/MS fragmentation methods or by 
inducing dissociation in solution via acid-induced denaturation. In addition, ESI MS 
spectrum of AT and FXa in the presence of native heparin showed evidence of higher 
order complexes; however the complex peaks were not resolved due to extensive 
heterogeneity. This experiment can be repeated using FTICR MS, and limited charge 
reduction method can be applied to isolate the complex peaks, and then determine the 
exact stoichiometry of the AT-FXa complexes.  
The complex formation between native heparin and AT was studied using limited 
charge reduction method on FTICR MS, and 1:1, 2:1 and 1:2 (AT:Hp) complexes were 
detected. This could show that there are multiple Hp binding sites on one AT, as well as 
multiple AT binding sites on one Hp.  The formation higher order complexes on the 
heparin chain can be studied by varying the solution mixing ratio between AT and Hp. 
Complementary to mass spectrometry, small-angle scattering techniques, such as small-
angle neutron scattering (SANS) or small angle X-ray scattering (SAXS) can be 
employed to determine size, shape and structure of the complexes. By this way, the 
proximity of the bound proteins on the Hp/HS chains can be detected.  
AT aggregation has been studied in the absence and in the presence of heparin 
and the morphology of the AT aggregates and AT-Hp complexes have shown different 
structural features, as revealed by the measured fractal dimensions in static light 
scattering (SLS). Small-angle scattering techniques, which accesses wider range of q-
values than SLS, could be used to probe the structural arrangements, correlation length 
and the dynamics of AT aggregates and higher order AT-Hp complexes.  
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